cms.bioaccessla.com

Tag: medtech

  • $8 Billion Of Pharma Capital Just Pointed At Argentina. What Medtech Founders Should Take From The May 29 CAEME Announcement.

    On May 29, 2026, the Cámara Argentina de Especialidades Medicinales (CAEME) announced jointly with President Javier Milei a six-year clinical research investment commitment from seven multinational pharmaceutical companies: Pfizer, Merck, Roche, Novartis, BMS, GSK, and Sanofi. The total commitment is USD 8 billion through 2032. On the same week, ANMAT’s Disposición 2978/2026, which cut import tariffs on medicines and medical devices by 50 to 70 percent, came into operative effect on June 1.

    For a Latin American clinical research operator that has spent 16 years arguing the case to MedTech and biotech founders, the May 29 to June 1 sequence is the strongest sovereign-level signal a Latin American country has produced for clinical research in the past decade. The data and the policy arrived in the same week. The Big Pharma capital and the regulator’s tariff cut arrived in the same week. The case Argentina has been building since Disposición 7516/25 first came into force in 2025 is now publicly endorsed by both seven multinational CEO offices and the federal executive.

    The interesting question is not whether founders should use Argentina for first-in-human (FIH) work. The interesting question is what happens to the Argentine clinical research ecosystem when USD 8 billion of pharma capital flows into a site base that, in 2026, has only 80 to 120 actively credentialed Phase 1/2 sites. This post unpacks the saturation thesis and what early-stage MedTech founders should be doing about it in 2026.

    The Site Saturation Math

    The CAEME pledge of USD 8 billion over 2026 to 2032 implies an average commitment of approximately USD 1.33 billion per year. At industry-average sponsored Phase 1 through 3 trial costs of USD 1 to 3 million per site per year for clinical operations and site fees, the pledge fully funds roughly 430 to 1,330 new trial-site-years annually if disbursed at the announced pace.

    Argentine clinical research currently runs at roughly 290 ANMAT-authorized trials per year (2025 throughput), with 1,188 active studies under ANMAT supervision and approximately 80 to 120 actively credentialed Phase 1/2 sites across all therapeutic areas. The pledge contemplates a 2.5x step-up in trial inflows against approximately the same site base.

    The implication is straightforward. By 2027, Argentine Phase 1/2 site capacity becomes the binding constraint on the system. Regulator throughput, which is already operative at 62 calendar days under Disposición 7516/25, is no longer the rate-limiting step. Site availability is. And site availability at top investigators compresses asymmetrically. A senior PI running three trials in 2026 does not move to six trials in 2027. A senior PI running three trials moves to four trials, while the marginal Phase 1/2 site backlog elongates by 6 to 12 months for the founders arriving last.

    Founders who lock in Argentine site relationships in 2026 are locking in the top quartile of investigators. Founders who arrive in 2027 are competing for what is left after Pfizer, Novartis, and the other CAEME signatories have claimed the senior beds.

    Why the Argentine Government Did This Now

    Three forces converged in 2026 that made the May 29 to June 1 sequence possible. First, the Milei administration’s broader productivity and quality agenda, codified in the proposed PCT (Productividad, Calidad y Transparencia) bill, created the legislative context for industry investment commitments. Second, ANMAT’s operational reform sequence, beginning with Disposición 7516/25 (62-day pathway, parallel ethics plus agency review, ICH E6(R3) alignment), reached a level of regulator credibility that multinationals could underwrite. Third, the comparative landscape moved against Argentina’s peer regulators. Colombia’s Ley 191 stalled in Comisión Séptima and is now effectively dead this term. Brazil’s ICH E6(R3) adoption remains on a slower trajectory than ANVISA’s 2024-2025 board sessions suggested. Mexico’s 30-day target announced at AMIIF on May 19 lacks DOF formalization. Argentina is the only major LATAM jurisdiction in 2026 with operative regulatory reform, operative tariff policy, and operative sovereign-level industry commitment in the same week.

    The PCT bill is the only caveat that matters. The CAEME pledge is contingent on PCT passage. As of June 1, the bill remains stalled. Founders evaluating Argentine sites should treat the regulatory and tariff case as the base case and the CAEME pledge as additive upside. Disposición 7516/25 and Disposición 2978/2026 are in force regardless.

    How to Sequence Argentina in 2026

    The country sequencing decision a MedTech founder makes in 2026 is structurally different than the same decision in 2024. Two years ago, the case for Argentine FIH rested on cost (USD 15,000 to 35,000 per patient versus USD 40,000 to 75,000 in the U.S. and Europe) and regulator throughput (62 days under 7516/25 versus 120 to 180 days under FDA EFS). Both arguments still apply, and the Disposición 2978/2026 tariff cut now removes a 4 to 8 percent additional cost layer on imported devices and study drugs.

    What is new in 2026 is the time pressure. The CAEME pledge does not change the operational case. It changes the urgency of the operational case. A founder who has been considering Argentine site selection for the past six months and has not yet executed is, beginning June 1, 2026, on the wrong side of a closing window. By Q4 2026, the same site relationships will be visibly competitive. By Q2 2027, the top-quartile PI list will be substantively claimed.

    For structural heart and cardiovascular device programs, the recommended sequence is Argentine site selection initiated by Q3 2026, ANMAT protocol filing by Q4 2026, first patient enrolled in Q1 2027. This sequence preserves access to the InCor São Paulo, Hospital Italiano Buenos Aires, and Fundación Cardiovascular Bogotá tier of cardiovascular research centers, with the Argentine arm operating in parallel with a U.S. EFS submission.

    For neuromodulation programs, the recommended sequence compresses further. Site selection at seed close (or post-Series A), ANMAT protocol filing within 90 days of site lock-in. The neuromodulation patient base in Argentina is concentrated at fewer specialized institutions than cardiovascular work, and the saturation pressure on neuromodulation-credentialed PIs is therefore more acute. Founders who have not selected Argentine neuromodulation sites by end of 2026 will likely face 6 to 9 month delays in 2027.

    For radiopharmaceutical and theranostics programs, the operational sequence is different in kind. Site selection has to be scoped before ANY other operational step because of isotope logistics, central pharmacy capacity, and credentialed nuclear medicine institutions. Radiopharma founders who wait until post-acceleration or post-Series A to scope LATAM partners have already added 6 to 9 months to their pivotal timeline. The Argentine radiopharma site base is even more concentrated than the neuromodulation base, and the CAEME pledge is highly likely to direct radiopharma-adjacent investment into the same handful of credentialed institutions.

    What This Means for the Colombia Case

    For bioaccess® and for any founder using a LATAM CRO with Colombian site depth, the May 29 to June 1 sequence forces an honest reassessment. Colombia in 2026 holds the following: established U.S.-trained PI density at specific institutions (Fundación Cardioinfantil, Fundación Valle del Lili, Universidad Javeriana), strong therapeutic-area depth in cardiovascular and oncology, INVIMA throughput at roughly 90 to 120 days. Colombia does not hold: operative sovereign-level investment commitment, modern ICH E6(R3) framework alignment (Resolución 8430/1993 remains the operative framework), or a recent tariff reduction comparable to Disposición 2978/2026.

    The Colombia case for 2026 is no longer “cheaper and faster.” The Colombia case is “specific therapeutic-area depth, U.S.-trained PI networks, and complementarity to an Argentine arm.” For founders running cardiovascular or oncology programs requiring U.S. data acceptance under FDA IDE pathways, the Colombian PI base remains uniquely qualified. For founders running neuromodulation or radiopharmaceutical programs at the FIH stage, the Argentine arm is now the primary recommendation, with Colombian sites operating as the complementary geography rather than the primary geography.

    This is a more nuanced positioning than the one bioaccess® and other LATAM CROs have historically used. It is also the positioning that will hold up over the next 12 to 18 months as the Argentine site saturation pressure builds.

    What Founders Should Do Before End of Q3 2026

    For MedTech, biotech, and radiopharma founders who have not yet scoped their LATAM site portfolio, the practical sequence over the next 90 days looks like:

    First, identify whether the program’s FIH country sequence is Argentina-primary, Argentina-secondary, or Argentina-complementary based on therapeutic area, regulatory pathway, and capital constraints. For structural heart and cardiac ablation, Argentina-primary or Argentina-secondary makes sense. For neuromodulation, Argentina-primary. For radiopharma, Argentina-primary with explicit isotope logistics scoping. For oncology devices with U.S. IDE pathway requirements, Argentina-complementary alongside Colombia or Brazil.

    Second, scope site availability at the institutions most likely to be impacted by the CAEME pledge. The largest pharma signatories (Pfizer, Roche, Novartis) historically work with a specific set of Argentine investigators in cardiology, oncology, and metabolism. Site availability at those investigators will compress first.

    Third, file ANMAT protocols on the Disposición 7516/25 parallel-review pathway. The 62-day timeline allows a 2026 Q3 site selection to produce first-patient-in by year-end. Delays beyond Q3 begin pushing first-patient-in into Q2 2027, by which point the competitive pressure on senior PIs will be visible in enrollment delays.

    Fourth, consider the Disposición 2978/2026 tariff cut as a planning input. The 50 to 70 percent reduction on imported devices and study drugs is most material for early-stage MedTech programs that import 80 to 100 percent of investigational supply. Plan device manufacturing and shipment timing to maximize the tariff savings.

    The Bottom Line

    Argentina did not become a clinical research hub on May 29, 2026. Argentina has been a clinical research hub for 30 years. What happened on May 29 to June 1, 2026, is that the federal executive, the regulator, and seven multinational pharma CEOs publicly aligned on the same operational thesis in the same week. That alignment compresses the founder decision window from years to quarters.

    For early-stage MedTech, biotech, and radiopharma founders evaluating LATAM FIH strategy, the operational reality is that the next 12 to 18 months are a sponsor-favorable market with multiple jurisdictions actively recruiting trial volume. Sponsors who position now benefit from regulator attention, expedited review windows, and access to the senior PI base. Sponsors who delay lose that window.

    The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong country sequence for their specific program. Argentina’s May 29 to June 1 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 LATAM FIH country sequencing decision and want a tailored proposal that incorporates the new ANMAT regulatory and tariff environment alongside Colombian and Brazilian complementary site options, the team at bioaccess® can produce a country-level model within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Partnering with ANVISA-Approved CROs for Medtech in Brazil: Essential Steps

    Partnering with ANVISA-Approved CROs for Medtech in Brazil: Essential Steps

    Introduction

    Navigating the intricate landscape of Brazil’s Medtech sector necessitates a profound understanding of the regulatory environment established by ANVISA. Companies aiming to introduce medical devices in this dynamic market can greatly benefit from collaborating with ANVISA-approved Contract Research Organizations (CROs). These organizations provide invaluable insights and streamlined processes for compliance.

    However, a pressing challenge persists: how can organizations effectively select the appropriate CRO and forge a successful partnership that accelerates their clinical studies while adhering to local regulations?

    This article delineates essential steps and best practices to ensure that Medtech companies can not only meet regulatory requirements but also flourish in Brazil’s competitive healthcare landscape.

    Understand Brazil’s Regulatory Framework for Medtech

    To successfully navigate the , it is essential to familiarize yourself with the (Agência Nacional de Vigilância Sanitária). This includes a thorough understanding of the classification of medical devices, the necessary documentation for submissions, and the timelines for approvals. Key steps in this process include:

    1. Research ANVISA Guidelines: Review the latest ANVISA guidelines for medical devices, focusing on the specific requirements pertinent to your product category.
    2. Identify Compliance Pathways: Determine whether your device falls under the new guidelines or existing frameworks, as Brazil has undergone significant recently.
    3. Prepare Required Documentation: Gather all necessary documents, including , technical specifications, and quality management system certifications.
    4. Consult with Specialists: Engage with compliance consultants or legal advisors who specialize in Brazilian Medtech regulations to ensure adherence and streamline the approval process. Partnering with for medtech in Brazil can significantly enhance your . Their comprehensive services encompass feasibility studies, site selection, compliance reviews, testing setup, import permits, project management, and reporting, ensuring a smoother pathway through the regulatory landscape. Additionally, leveraging the expertise of professionals like Ana Criado and Katherine Ruiz can provide valuable insights into navigating the complexities of the Brazilian market.

    Each box represents a step in the regulatory process for Medtech in Brazil. Follow the arrows to understand the sequence of actions you need to take to ensure compliance with ANVISA regulations.

    Select the Right ANVISA-Approved CRO for Your Needs

    Selecting the right CRO is essential, and partnering with is critical for the success of your clinical studies. To guide your decision-making process, consider the following essential steps:

    1. Assess Experience and Expertise: Prioritize CROs like , which boast a strong track record in managing clinical trials for medical devices similar to yours. Their expertise in ANVISA submissions and , including swift site activation and adherence to FDA/EMA/MDR standards, are crucial for effectively navigating the compliance landscape. The new governance framework in Brazil, which compared to previous frameworks, highlights the significance of partnering with .
    2. : Choose a CRO that possesses an extensive understanding of Brazil’s compliance framework and market dynamics. Local subject matter experts can provide invaluable insights into compliance specifics and cultural nuances that significantly enhance research efficiency and patient enrollment.
    3. : Collect feedback from former clients to assess the CRO’s reliability, communication skills, and overall performance. Positive testimonials can shed light on their operational effectiveness and the impact of their local expertise on achieving success.
    4. Consider Service Offerings: Ensure the CRO provides a comprehensive suite of services tailored to your specific needs, including . A robust service portfolio, such as the one offered by , can streamline your initiative and bolster adherence to local regulations, covering everything from feasibility studies to management and reporting.
    5. Conduct Interviews: Engage in discussions with potential CROs to evaluate their approach, team capabilities, and alignment with your project objectives. This interaction will help you gauge their commitment and suitability for your clinical study. As the Content Team states, “Your choice of CRO partner significantly impacts research success.”
    6. : Acquaint yourself with the introduced by RDC 837/2023, which permits trials to proceed based on ethics committee approval if ANVISA does not respond within 90 days. This knowledge can influence your selection process and ensure the timely initiation of your endeavor.

    This flowchart outlines the key steps to take when choosing a CRO. Follow the arrows to see the process from assessing expertise to understanding regulatory mechanisms, ensuring you cover all necessary aspects for a successful partnership.

    Establish a Partnership: Steps to Collaborate with Your Chosen CRO

    To establish a successful partnership with your chosen , it is imperative to follow these essential steps:

    1. : Clearly articulate the partnership’s goals, including specific timelines, deliverables, and metrics for success. This clarity aligns both parties and sets a foundation for accountability.
    2. : Develop a detailed contract that outlines the scope of work, responsibilities, payment terms, and confidentiality clauses. A well-structured agreement minimizes misunderstandings and fosters smoother collaboration.
    3. : Implement regular meetings and reporting structures to maintain open lines of communication and ensure transparency throughout the initiative. Effective communication is crucial for addressing issues promptly and keeping all stakeholders informed.
    4. Assign Roles and Responsibilities: Clearly delineate the roles of your team and the to prevent overlaps and ensure accountability. This clarity enhances and aids in tracking progress effectively.
    5. Foster a Collaborative Culture: Promote an environment of open dialogue and teamwork between both teams. can significantly improve problem-solving skills and outcomes.

    Statistics indicate that and retention rates of up to 95%, underscoring the value of a well-defined collaboration framework. By adhering to these steps, you can enhance the potential of your partnership, particularly through , and achieve successful results in your .

    Each box represents a crucial step in forming a partnership with a CRO. Follow the arrows to see the order in which these steps should be taken to ensure a successful collaboration.

    Manage the Partnership: Best Practices for Effective Collaboration

    To ensure a successful and productive partnership with your CRO, it is essential to implement the following :

    1. Maintain Open Lines of Communication: Regularly check in with your CRO to discuss progress, challenges, and any necessary modifications to the plan. Effective communication is vital; studies indicate that organizations with robust communication practices experience a .
    2. : Track key performance indicators (KPIs) such as to evaluate the CRO’s performance and ensure alignment with objectives. For instance, organizations that actively monitor these metrics can , significantly enhancing trial efficiency.
    3. Be Responsive to Feedback: Encourage feedback from both your team and the CRO, and be willing to make adjustments based on constructive criticism. This responsiveness fosters a cooperative atmosphere, which is crucial for overcoming challenges and attaining goals.
    4. Celebrate Milestones: Acknowledge and celebrate key achievements throughout the endeavor to foster a positive working relationship. Recognizing milestones not only enhances morale but also strengthens dedication to the success of the endeavor.
    5. : Develop a to address potential challenges that may arise during the partnership, ensuring both parties are prepared to adapt. Proactive contingency planning can mitigate risks and enhance the overall resilience of the project.

    In this mindmap, the central idea is the best practices for collaboration. Each branch represents a specific practice, and the sub-points detail what that practice involves. Follow the branches to understand how each contributes to a successful partnership.

    Conclusion

    Navigating the complexities of the Brazilian Medtech landscape necessitates a strategic approach, especially when collaborating with ANVISA-approved CROs. Successful partnerships hinge on:

    1. A comprehensive understanding of the regulatory framework
    2. The careful selection of the right CRO
    3. The establishment of a robust partnership

    By concentrating on these essential elements, organizations can significantly enhance their clinical study management and ensure compliance with local regulations.

    Key arguments underscore the necessity of:

    • Thorough research into ANVISA guidelines
    • The imperative of selecting a CRO with local expertise
    • The critical role of clear communication and defined objectives in partnership agreements

    Moreover, best practices such as monitoring performance metrics and being responsive to feedback are vital for cultivating a productive working relationship. Collectively, these insights highlight the importance of meticulous planning and execution within the Medtech sector.

    Ultimately, the path to successful Medtech endeavors in Brazil is profoundly influenced by the choice of CRO and the strength of the established partnership. By embracing these strategies, organizations not only streamline the regulatory process but also enhance their potential for innovation and growth within the industry. Stakeholders are urged to take decisive action by thoroughly assessing their options and committing to best practices that will foster impactful collaborations in the Brazilian healthcare market.

    Frequently Asked Questions

    What is the role of ANVISA in Brazil’s Medtech landscape?

    ANVISA (Agência Nacional de Vigilância Sanitária) is the regulatory authority responsible for establishing key regulations for medical devices in Brazil, which includes classification, documentation requirements, and approval timelines.

    What should I do to understand the regulations for medical devices in Brazil?

    To understand the regulations, you should research the latest ANVISA guidelines for medical devices, focusing on the specific requirements related to your product category.

    How can I identify the compliance pathways for my medical device?

    You can identify compliance pathways by determining whether your device falls under the new guidelines or existing frameworks, as Brazil has seen significant regulatory changes recently.

    What documentation is required for submitting a medical device to ANVISA?

    The required documentation includes clinical data, technical specifications, and quality management system certifications.

    Why is it important to consult with specialists when navigating Brazil’s Medtech regulations?

    Consulting with compliance consultants or legal advisors who specialize in Brazilian Medtech regulations is important to ensure adherence to regulations and to streamline the approval process.

    How can partnering with ANVISA-approved CROs benefit my clinical study management in Brazil?

    Partnering with ANVISA-approved CROs can enhance clinical study management by providing comprehensive services such as feasibility studies, site selection, compliance reviews, testing setup, import permits, project management, and reporting.

    Who are some professionals that can provide insights into navigating the Brazilian Medtech market?

    Professionals like Ana Criado and Katherine Ruiz can provide valuable insights into navigating the complexities of the Brazilian Medtech market.

    List of Sources

    1. Select the Right ANVISA-Approved CRO for Your Needs
      • bioaccessla.com (https://bioaccessla.com/blog/7-leading-latin-america-cros-revolutionizing-clinical-research)
      • meddeviceonline.com (https://meddeviceonline.com/doc/brazil-s-regulatory-revolution-how-new-laws-are-transforming-medical-device-clinical-trials-0001)
      • meddeviceonline.com (https://meddeviceonline.com/doc/brazil-s-competitive-edge-infrastructure-and-operational-advantages-for-medical-device-trials-0001)
      • Clinical Trials Statistics By Phases, Definition and Interventions (2026) (https://media.market.us/clinical-trials-statistics)
      • Clinical Trials Market Size, Share, Growth Report, 2026-2033 (https://grandviewresearch.com/industry-analysis/global-clinical-trials-market)
    2. Establish a Partnership: Steps to Collaborate with Your Chosen CRO
      • clinicaltrialsarena.com (https://clinicaltrialsarena.com/news/best-practices-for-study-team-interactions-and-communications-between-sponsor-and-cros-4688745-2)
      • fortunebusinessinsights.com (https://fortunebusinessinsights.com/brazil-clinical-trials-market-112310)
      • bioaccessla.com (https://bioaccessla.com/blog/choosing-clinical-trial-partners-in-latin-america-best-practices-and-expert-insights)
      • clinicaltrialsarena.com (https://clinicaltrialsarena.com/news/writing-the-best-rfp-to-attract-the-relevant-service-providers-5881131-2)
    3. Manage the Partnership: Best Practices for Effective Collaboration
      • scribd.com (https://scribd.com/document/139268588/Case-Study-Report)
      • bioaccessla.com (https://bioaccessla.com/br/blog/how-to-ensure-compliance-for-clinical-trials-under-cofepris-a-step-by-step-guide)
      • lineardesign.com (https://lineardesign.com/blog/cro-statistics)

  • Argentina Just Cut Clinical Trial Import Costs By 50 70%. Here’s What 290 Authorized Trials In 2025 Tell Founders.

    On May 19, 2026, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026. The preamble of the instrument states the policy goal explicitly: to attract clinical trial investment to Argentina. The next day, the Argentine government released throughput data that explained why the policy was built: 290 clinical trials authorized in 2025, a 12 percent year-over-year increase, with 114 already authorized in the first quarter of 2026 and 1,188 active studies under ANMAT supervision. Argentina is now formally branding itself an “internationally competitive clinical research hub.”

    For a Latin American clinical research operator who has spent 16 years arguing the speed-and-cost case to MedTech and biopharma founders, the May 19-20 sequence is the most unusual validation event the regulatory landscape has produced this decade. Most LATAM clinical research positioning is CRO marketing. Argentina’s came from the regulator itself, in the preamble of a binding instrument, on government letterhead, with throughput numbers attached. That is not the same kind of evidence as a competitive pitch deck.

    For founders running a 10-patient first-in-human (FIH) device study, the math now stacks in a way that materially changes the country sequencing decision. This post unpacks what changed, what stayed the same, and how founders pursuing a U.S. Early Feasibility Studies (EFS) plus out-of-U.S. (OUS) FIH strategy should think about Argentina in 2026.

    What Changed on May 19, 2026

    Disposición 2978/2026 is the binding instrument. The tariff reduction applies across the import basket relevant to clinical research operations, including investigational drugs, medical devices in trial-supply quantities, reference standards, and disposable consumables tied to study protocols. The pre-existing effective duty rate for imported medical devices in Argentina ranged from 12 to 18 percent before May 19. Under the new schedule, that effective rate compresses to roughly 6 to 12 percent for trial-supply imports, with category-specific reductions ranging from 50 to 70 percent depending on the harmonized system classification.

    On its own, the tariff cut is meaningful. It is more meaningful in combination with the operational baseline Argentina already had in place. Disposición 7516/2025, which came into force in 2025 and is fully aligned with ICH E6(R3), caps clinical trial protocol authorization at 62 calendar days (45 working days maximum). That includes parallel ethics committee review and ANMAT agency review, not sequential review. For comparison, the U.S. EFS pathway typically runs 120 to 180 days from IDE submission to first patient enrolled. Argentina’s ANMAT pathway is 60 to 120 days faster, depending on the comparison case.

    The April 24, 2026 importación simplification further compresses pre-first-patient timelines by removing roughly 14 to 21 days of customs and import-classification delay that previously sat between protocol approval and the actual arrival of study material at site. The June 1, 2026 tariff reduction now removes the cost penalty that previously sat alongside that delay.

    The Throughput Number Most Founders Miss

    The 290-trials-in-2025 figure deserves more attention than it has received. Of those 290 authorizations, the regulator-reported mix is approximately 70 percent biopharma and 30 percent medical device or combination product. The Q1 2026 pace of 114 authorizations annualizes to roughly 456 trials per year, which would represent a 57 percent year-over-year acceleration if sustained. Even if the run rate moderates by half, Argentina’s 2026 throughput will exceed all prior years on record.

    For a founder evaluating site capacity risk, the 1,188 active studies under ANMAT supervision is the more strategic data point. Argentina has the patient-volume depth and the principal-investigator network density to absorb new sponsor demand without the recruitment friction that emerging-market sites with thinner trial histories often impose. A FIH MedTech sponsor running a 10-patient study at two Argentine sites can realistically expect first-patient-in within 90 days of protocol approval, and last-patient-in within 5 to 7 months of contract execution. Those numbers have been stable across the last 36 months of bioaccess® operational experience.

    The Cost Math, Refreshed

    Pre-May 19, 2026, the LATAM per-patient cost range for a FIH MedTech study sat at $15,000 to $35,000, compared to $40,000 to $75,000 in the U.S. and Europe. For a 10-patient FIH device study, that is a $250,000 to $400,000 absolute swing, sufficient on its own to fund roughly four months of clinical operations headcount or a complete adaptive design biostatistics package.

    The June 1 tariff reduction does not move the per-patient labor cost. It moves the device and drug-import cost component, which typically represents 8 to 15 percent of total study cost for a MedTech FIH trial relying on imported investigational devices. A 50 percent reduction on that line item produces a 4 to 8 percent reduction on total study cost, which compounds with the labor cost advantage Argentina already offered. On a $250,000 study, that is an additional $10,000 to $20,000 of effective savings. On a $1 million pivotal-stage Argentine arm of a multi-country trial, the effect grows proportionally.

    The strategic value is not the headline savings number. It is the regulatory clarity that the tariff cut produces. Sponsors evaluating Argentina now know that the regulator has formally committed to clinical research as a strategic policy priority. That changes how a CFO evaluates jurisdiction risk in the IND-enabling phase.

    The Database Anomaly and How to Work Around It

    One operational caveat is worth flagging directly. ANMAT’s public pharmacology database, which historically served as the citable reference for trial throughput and status, remains anchored at a September 30, 2025 data cutoff. As of the publication date of this post, that anomaly has persisted for four consecutive weekly review cycles. The most likely explanation is a backend migration tied to the broader Argentine government’s digital transformation initiative, but the database itself does not yet reflect Q4 2025 or any 2026 data.

    For sponsors building a regulatory dossier or a board pack that requires citable Argentine clinical research throughput data, the May 20, 2026 government statistics package, available through argentina.gob.ar communications channels, is now the more authoritative source than the database. For real-time individual study status, the RENIS (Registro Nacional de Investigaciones en Salud) registry, accessible through the SISA portal, remains operative and current. Disposición 7516/25, the 62-day pathway, the importación simplification, and Disposición 2978/2026 are all fully in force regardless of the database refresh status.

    How to Sequence Argentina in a U.S. EFS Plus OUS FIH Strategy

    The most common 2026 founder question is whether to run U.S. EFS first, OUS FIH first, or both in parallel. The May 19-20 Argentina updates do not change the answer in every case, but they change it in enough cases that the question is worth re-examining.

    For structural heart, neuromodulation, and radiopharmaceutical or theranostic FIH programs, where the U.S. EFS pathway involves an IDE submission with 120 to 180 day review timelines, the parallel Argentina arm is now substantially more attractive. The argument runs as follows: a sponsor who files the IDE with FDA in month one and simultaneously files the ANMAT protocol under Disposición 7516/25 will, in a typical case, have ANMAT approval and first-patient-in achieved before the FDA has finished its initial IDE review. That bridge data, if collected against an FDA-aligned endpoint set, materially strengthens the IDE review and accelerates the post-IDE clinical trial path.

    The bridge data approach assumes the sponsor designs the Argentine arm to match the FDA-expected endpoints from the outset. That is not a regulatory obligation in Argentina, but it is the operational discipline that converts a 62-day pathway into a strategic asset rather than a parallel cost center. ICH M11 CeSHarP, finalized by ICH on May 21, 2026, makes that endpoint-aligned protocol authoring substantially more efficient than it was a year ago.

    For absorbable implants, cardiac ablation, and oncology device FIH programs, the Argentina arm makes sense as the primary FIH site set, with the U.S. EFS following as a confirmatory phase rather than as the primary first-in-human exposure. The 2026 tariff reduction further tips the math in this direction for sponsors with capital constraints between Series A and Series B.

    What This Means for the Latin American Clinical Research Landscape

    Argentina’s May 19-20 sequence is the clearest example to date of a Latin American regulator choosing, in policy, to compete for clinical research investment. Brazil, Mexico, and Colombia have made similar moves in the past 24 months, but none have packaged a binding tariff reduction with a coordinated government statistics release in the same week. The combination is what makes the Argentine moment unusual.

    For Latin American CROs, the strategic implication is that the next 12 to 18 months will likely be a sponsor-favorable market, with multiple jurisdictions actively recruiting trial volume. Sponsors who position now will benefit from regulator attention, expedited review windows, and the willingness of agencies to engage with novel trial designs at the pre-submission stage. Sponsors who delay until the policy environment has fully stabilized will lose the strategic window.

    For bioaccess® and other LATAM operators, the implication is that the value proposition has moved beyond cost and speed into regulatory partnership. The conversation a founder needs to have with their CRO in 2026 is no longer about how fast the trial can run. It is about how the trial design, the country sequence, and the data architecture combine to compress the Innovation Runway, the operational window between a founder’s first FIH decision and the data package their next funding round requires.

    The Bottom Line for Founders

    Argentina has just made the clearest policy statement any Latin American clinical research regulator has produced in 2026. The 62-day pathway under Disposición 7516/25 is operative. The importación simplification is in force. The 50 to 70 percent tariff reduction on imported medicines and medical devices begins June 1. The throughput data confirms that the regulatory environment can absorb new sponsor demand at scale.

    For a MedTech, biotech, or radiopharma founder evaluating a 2026 FIH country sequencing decision, the Argentine arm now warrants serious consideration as the lead site or the parallel site for any program where the U.S. EFS pathway is the comparison baseline. The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong study to run first. Argentina’s May 19-20 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 FIH sequencing decision and want a country-level model that reflects the new Argentina policy environment, the team at bioaccess® can produce a tailored proposal within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Navigate MedTech Clinical Trials in Bolivia: A Step-by-Step Guide

    Navigate MedTech Clinical Trials in Bolivia: A Step-by-Step Guide

    Introduction

    Navigating the complexities of medtech clinical trials in Bolivia can be daunting, yet it holds immense potential for those who understand the landscape. With a regulatory framework overseen by the National Authority of Medicines and Health Technologies (AGEMED), grasping the essential steps can significantly enhance the chances of successful trial outcomes. What if researchers could streamline their processes despite evolving regulations and patient recruitment hurdles? This guide provides a comprehensive roadmap for conducting clinical trials in Bolivia, empowering stakeholders to harness the region’s strengths in speed, cost efficiency, and patient engagement.

    Understand the Regulatory Framework for Clinical Trials in Bolivia

    Understanding the regulatory landscape in Bolivia is crucial for the success of medtech clinical trial Bolivia. Navigating research studies here requires a comprehensive grasp of the framework established by the National Authority of Medicines and Health Technologies (AGEMED). This authority oversees the approval and monitoring of research studies, ensuring compliance with local laws and international standards such as ICH-GCP. Here are the essential steps to effectively navigate this regulatory landscape:

    1. Familiarize Yourself with AGEMED: Access the AGEMED website to review guidelines and requirements for medical studies. A clear understanding of their processes will facilitate smoother submissions.
    2. Review Relevant Legislation: Examine the laws governing medical research in Bolivia, especially the General Health Law, which outlines the regulatory environment for medical devices and pharmaceuticals, including aspects relevant to medtech clinical trial Bolivia.
    3. Identify Required Approvals: Determine the necessary approvals from AGEMED, including ethics committee review and research registration, which are critical for compliance.
    4. Understand Submission Timelines: AGEMED typically requires 4-8 weeks for the initial review and approval of research study applications. Delays in approval can derail research timelines, making it essential to plan ahead.
    5. Stay Updated on Changes: Regulatory frameworks are subject to change, so it is vital to regularly check for updates from AGEMED and other relevant authorities to ensure ongoing compliance.

    Recently, AGEMED has streamlined its processes. The technical and scientific review phase now takes between 6 and 16 months, depending on study complexity. Successful case studies demonstrate that well-prepared submissions can significantly reduce approval times. By investing time in preparation, researchers can expedite their studies and enhance their chances of success. By adhering to these guidelines, researchers can tap into the advantages Latin America offers, including faster timelines and cost savings for early-stage studies.

    Each box represents a step you need to take to successfully navigate the regulatory landscape for clinical trials. Follow the arrows to see the order in which you should complete these steps.

    Prepare Essential Documentation and Compliance Measures

    Understanding the regulatory framework is just the beginning; preparing the right documentation is crucial for the success of your medtech clinical trial in Bolivia. This includes:

    1. Clinical Trial Protocol: Develop a comprehensive protocol that outlines the study design, objectives, methodology, and endpoints. This document must follow ICH-GCP guidelines. Doing so ensures the trial is conducted ethically and scientifically.
    2. Informed Consent Forms: Create clear and concise informed consent forms that comply with ethical standards. These forms must ensure that participants fully understand the study’s purpose, risks, and benefits, which is crucial for ethical compliance and participant safety.
    3. Investigator’s Brochure: Compile an investigator’s brochure that provides detailed information about the investigational product, including preclinical and clinical data. This document serves as a vital resource for investigators and regulatory bodies.
    4. Regulatory Submission Dossier: Prepare a submission dossier that includes all required documents, such as the protocol, informed consent forms, and investigator’s brochure, formatted according to AGEMED’s guidelines. This dossier is essential for obtaining the necessary approvals to initiate the trial.
    5. Compliance Checklists: Utilize compliance checklists to ensure all documentation meets AGEMED’s requirements before submission. Taking this proactive approach can prevent delays in the approval process, which usually takes 4-8 weeks here-much quicker than in many other regions. Leveraging bioaccess®‘s expertise in navigating these regulatory pathways can further streamline the process.

    Following these guidelines boosts your chances of successful protocol submissions for medtech clinical trial Bolivia and other early-stage studies in Latin America. You can take advantage of the region’s strategic benefits, including speed, cost efficiency, and effective patient recruitment.

    This flowchart outlines the steps you need to take to prepare for a clinical trial. Each box represents a key document or action, and the arrows show the order in which you should complete them. Following this process will help ensure that your trial is compliant and ready for approval.

    Implement Effective Patient Recruitment Strategies in Bolivia

    In Bolivia, effective patient recruitment is essential for the success of the medtech clinical trial Bolivia research studies. Here are strategies to enhance your recruitment efforts:

    1. Engage Local Communities: Collaborate with local healthcare providers and community organizations to raise awareness about the study and its benefits. This grassroots method builds trust and encourages involvement. It’s crucial, especially since only 32% of patients report being informed about research studies by their physicians. Additionally, limited budgets can severely restrict recruitment efforts, making community engagement even more vital.
    2. Utilize Digital Platforms: Leverage social media and online patient databases to reach potential participants. Tailor your messaging to resonate with local culture and language, as 80% of internet users search for health information online. This digital outreach is particularly important in addressing challenges such as lack of awareness and access to information, which can significantly impact recruitment success.
    3. Offer Incentives: Think about offering incentives like transportation reimbursement or health check-ups to make participation easier. This can be particularly effective in addressing the logistical challenges that often deter participation.
    4. Conduct Outreach Programs: Organize informational sessions in local communities to educate potential participants about the study, addressing any concerns they may have. Engaging with the community directly can significantly enhance trust and willingness to participate.
    5. Monitor Recruitment Progress: Regularly assess recruitment metrics and adjust strategies as needed to ensure you meet enrollment targets within the planned timelines. Given that 86% of clinical studies experience delays, proactive monitoring can help mitigate risks associated with recruitment shortfalls. Without effective recruitment strategies, studies risk delays that can jeopardize their success.
    6. Understand Regulatory Requirements: Familiarize yourself with the regulatory landscape in the region, including the stipulations set forth by INVIMA. Grasping approval timelines and compliance criteria, such as ICH-GCP standards, is vital for effectively navigating the research process.

    By applying these methods, the medtech clinical trial Bolivia can utilize local involvement and digital resources to improve recruitment effectiveness, ultimately resulting in successful research outcomes.

    This mindmap illustrates various strategies for recruiting patients in clinical trials. Start at the center with the main topic, then follow the branches to explore each strategy and its specific actions. Each color represents a different strategy, making it easy to see how they connect to the overall goal.

    Conduct Clinical Trials While Ensuring Compliance and Efficiency

    Navigating the complexities of the medtech clinical trial Bolivia requires a strategic approach to compliance and operational efficiency. Here are key practices to follow:

    1. Establish a Compliance Framework: Develop a comprehensive compliance framework that outlines procedures for adhering to AGEMED regulations and ICH-GCP guidelines throughout the research process.
    2. Train Research Staff: Ensure that all research staff receive thorough training in compliance requirements and ethical standards. Regular training sessions are essential for maintaining high standards of practice and ensuring that staff are well-versed in the latest regulatory updates.
    3. Implement Data Management Systems: Utilize robust data management systems to track participant data, monitor progress of the study, and ensure data integrity. Such technology can streamline reporting and compliance checks, enhancing overall study efficiency.
    4. Conduct Regular Audits: Schedule routine internal inspections to evaluate adherence to protocols and legal requirements. Promptly addressing any discrepancies is vital for maintaining study integrity and ensuring adherence to ethical standards.
    5. Engage with Oversight Entities: Maintain open communication with AGEMED and other pertinent oversight bodies throughout the study. This proactive approach facilitates smoother interactions and quicker resolutions to any issues that may arise, ultimately supporting the success of the study.

    These strategies not only enhance compliance but also position research teams for success in a competitive landscape. Moreover, conducting assessments in Latin America provides substantial benefits such as approvals in only 4-8 weeks compared to over 6 months in the US/EU, leading to quicker patient recruitment and cost-effectiveness. With potential savings of $25K per patient and 30% lower overall trial costs, utilizing these advantages can make medtech clinical trial Bolivia an appealing option for MedTech and Biopharma companies. Furthermore, subscribing to Global Trial Accelerators™ can provide essential insights and market access strategies that further support clinical research directors in their decision-making processes.

    The center of the mindmap shows the main focus on clinical trials. Each branch represents a key practice to enhance compliance and efficiency, with further details available as you explore each branch. This layout helps you understand how each practice contributes to the overall success of clinical trials.

    Conclusion

    Navigating the complex regulatory landscape of medtech clinical trials in Bolivia can be both challenging and rewarding for researchers. Understanding the regulatory framework is crucial. Preparing essential documentation and implementing effective patient recruitment strategies can significantly enhance researchers’ chances of success. This guide emphasizes the importance of thorough preparation and compliance with AGEMED’s local regulations. Such diligence streamlines the approval process and expedites research timelines.

    Key strategies include:

    1. Familiarizing oneself with AGEMED’s requirements
    2. Developing comprehensive trial protocols
    3. Engaging local communities to boost recruitment efforts

    Compliance with ICH-GCP guidelines ensures that trials are conducted ethically and efficiently. By utilizing digital platforms and offering incentives, researchers can effectively reach potential participants, addressing common challenges in patient recruitment.

    The evolving medtech field presents a promising opportunity for conducting clinical trials in Bolivia. The region offers faster approval timelines and cost-effective solutions while enhancing patient recruitment through localized engagement. Embracing these strategies can position research teams for success while capitalizing on the strategic advantages that Latin America provides for early-stage clinical trials. Stakeholders who adapt to this evolving landscape will not only enhance their research outcomes but also contribute to the advancement of medtech innovation in the region.

    Frequently Asked Questions

    What is the role of AGEMED in clinical trials in Bolivia?

    AGEMED, the National Authority of Medicines and Health Technologies, oversees the approval and monitoring of clinical trials in Bolivia, ensuring compliance with local laws and international standards such as ICH-GCP.

    How can researchers familiarize themselves with AGEMED’s requirements?

    Researchers should access the AGEMED website to review guidelines and requirements for medical studies, which will help facilitate smoother submissions.

    What legislation governs medical research in Bolivia?

    The General Health Law outlines the regulatory environment for medical devices and pharmaceuticals in Bolivia, which is essential for understanding the legal framework for clinical trials.

    What approvals are necessary for conducting clinical trials in Bolivia?

    Researchers must obtain necessary approvals from AGEMED, including ethics committee review and research registration, which are critical for compliance.

    What are the typical submission timelines for research study applications to AGEMED?

    AGEMED typically requires 4-8 weeks for the initial review and approval of research study applications, but the technical and scientific review phase can take between 6 and 16 months depending on study complexity.

    How can researchers expedite their approval process with AGEMED?

    Well-prepared submissions can significantly reduce approval times, so investing time in preparation is essential for expediting studies and enhancing chances of success.

    Why is it important to stay updated on regulatory changes in Bolivia?

    Regulatory frameworks are subject to change, making it vital for researchers to regularly check for updates from AGEMED and other relevant authorities to ensure ongoing compliance.

    What advantages does conducting clinical trials in Latin America offer?

    Latin America provides advantages such as faster timelines, cost savings, and efficient patient recruitment for early-stage clinical trials, making it an attractive option for researchers.

    List of Sources

    1. Understand the Regulatory Framework for Clinical Trials in Bolivia
      • omcmedical.com (https://omcmedical.com/blog/bolivia-medical-device-registration-process-timelines)
      • scrconsultings.com (https://scrconsultings.com/stability-studies-bolivia-agemed-guideline)
      • pharmaboardroom.com (https://pharmaboardroom.com/legal-reports/the-pharma-legal-handbook-bolivia)
      • bioaccessla.com (https://bioaccessla.com/blog/5-steps-for-regulatory-compliance-for-medtech-trials-in-bolivia)
    2. Prepare Essential Documentation and Compliance Measures
      • ccrps.org (https://ccrps.org/clinical-research-blog/how-to-write-a-clinical-trial-protocol)
      • desiaclinical.com (https://desiaclinical.com/library/basic-information-about-clinical-trials-32)
      • clinicaltrialrisk.org (https://clinicaltrialrisk.org/clinical-trial-design/protocol-design-for-clinical-trials-the-complete-checklist)
    3. Implement Effective Patient Recruitment Strategies in Bolivia
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • 10 Inspiring Patient Experience Quotes | Relias (https://relias.com/blog/patient-experience-quotes)
      • nclusiv.co.uk (https://nclusiv.co.uk/edi-consulting/f/patient-engagement-quotes-for-every-purpose-audience)
      • Enrollment in Clinical Trials: Statistics and Patient Recruitment Strategies | Power (https://withpower.com/guides/enrollment-in-clinical-trials-statistics-and-patient-recruitment-strategies)
      • Evaluation of factors associated with recruitment rates in early phase clinical trials based on the European Clinical Trials Register data (https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13659)
    4. Conduct Clinical Trials While Ensuring Compliance and Efficiency
      • 70 Research Quotes to Inspire Your Work – Qualtrics (https://qualtrics.com/articles/strategy-research/research-quotes)
      • Number of clinical trials by year, country, region and income group (https://who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-clinical-trials-by-year-country-who-region-and-income-group)
      • nclusiv.co.uk (https://nclusiv.co.uk/edi-consulting/f/patient-engagement-quotes-for-every-purpose-audience)
      • goodreads.com (https://goodreads.com/quotes/tag/clinical-trials)

  • 10 Key Insights for MedTech Clinical Trials in Cuba

    10 Key Insights for MedTech Clinical Trials in Cuba

    Introduction

    Cuba’s MedTech landscape is not just evolving; it’s presenting a complex web of challenges and opportunities for clinical trials. As the country streamlines its regulatory processes and enhances its healthcare infrastructure, MedTech companies are increasingly drawn to its cost-effective and efficient trial environment. Navigating this evolving landscape poses significant challenges for organizations. How can they turn these challenges into opportunities? Let’s explore ten key insights that can help MedTech firms tap into Cuba’s strategic advantages for early-stage clinical trials, ensuring compliance and fostering innovation in a promising market.

    Understand Cuba’s Regulatory Landscape for MedTech Trials

    Navigating the medtech clinical trial Cuba regulatory landscape presents both challenges and opportunities for clinical research. Cuba’s regulatory system for MedTech research studies is overseen by the Center for State Control of Medicines, Equipment and Medical Devices (CECMED). This authority plays an essential role in assessing and sanctioning medical studies, ensuring compliance with international standards such as ICH-GCP. To commence a clinical study, applicants must submit a comprehensive dossier that includes preclinical data, ethical approvals, and a detailed study protocol. CECMED’s application process is efficient. Regulatory approval often occurs within 30 to 90 days, making it notably faster than in many other regions.

    CECMED has modified its processes to speed up approvals, particularly emphasized during the COVID-19 pandemic when it permitted emergency use for vaccines like Abdala, based on data from earlier phases of evaluation. This adaptability showcases CECMED’s commitment to maintaining high standards while responding to urgent public health needs. The authority’s efficient strategy not only enables faster research timelines but also guarantees that all medicines and devices comply with WHO standards, strengthening the nation’s ability to autonomously address its health issues.

    Are you an organization looking to perform medical studies in Cuba? Understanding the specific criteria and schedules is crucial. CECMED’s structured approval process, along with Cuba’s strategic advantages in patient recruitment and cost efficiency, makes it an attractive location for a medtech clinical trial Cuba in early-stage clinical research. By leveraging insights from Global Trial Accelerators™, MedTech startups can navigate the regulatory landscape effectively and capitalize on the unique opportunities available in Latin America. Understanding these dynamics could be the key to unlocking successful clinical trials in Cuba.

    This flowchart guides you through the steps needed to get approval for MedTech clinical trials in Cuba. Each box represents a key action, and the arrows show the order in which you should complete them. If your application is approved, you can move forward with your trial; if not, you'll need to revise your submission.

    Recognize the Importance of First-in-Human Trials in Cuba

    First-in-human (FIH) studies are not just a regulatory requirement; they are a pivotal step in ensuring the safety and efficacy of MedTech innovations. In the island nation, these assessments hold particular importance due to the strong healthcare infrastructure, marked by a dedication to medical research and a highly skilled clinical workforce. The variety of the patient population in the region often exceeds that found in other areas, improving the generalizability of research outcomes. This diversity enhances data quality and makes findings more appealing to investors and regulatory bodies.

    Furthermore, successful FIH studies in the region can lead to accelerated market entry and enhanced funding possibilities. The oversight framework in the island nation facilitates efficient execution of studies, with streamlined routes for approvals that conform to international standards like ICH-GCP. Regulatory bodies such as INVIMA aid in adherence to these standards, ensuring that studies fulfill the necessary criteria for FDA acceptance. With this regulatory framework and a strong focus on healthcare innovation, the island is becoming a go-to hub for MedTech companies looking to conduct early-stage assessments.

    As of 2026, the environment for MedTech studies in the region continues to progress, with a growing number of companies acknowledging the advantages of utilizing local expertise and patient diversity. Engaging in medtech clinical trial Cuba not only accelerates the development process but also enhances the likelihood of positive outcomes, ultimately facilitating the transition from research to real-world applications. However, the challenge of engaging older adults in research remains a significant barrier, highlighting the need for targeted recruitment strategies. Integrating insights from specialists can really boost how we conduct FIH studies in this promising environment. Testimonials from clients who have successfully navigated the Innovation Runway underscore the effectiveness of this approach, showcasing real-world success stories that enhance credibility. Addressing these challenges with targeted strategies will not only improve participation but also elevate the quality of clinical research outcomes.

    This mindmap illustrates the key aspects of First-in-Human trials in Cuba. Start at the center with the main topic, then explore the branches to see how different elements like regulations, healthcare quality, and patient diversity contribute to the overall importance of these trials.

    Leverage Streamlined Regulatory Pathways for Faster Approvals

    Navigating the regulatory landscape in Cuba can be daunting, yet it offers unique opportunities for firms involved in medtech clinical trial Cuba. Cuba offers streamlined pathways that greatly accelerate medtech clinical trial Cuba approvals, enabling MedTech companies to obtain feedback and approvals in as few as 30 days. This rapid process stems from CECMED’s dedication to innovation. It focuses on developing new medical technologies. To make the most of these fast-tracked pathways, companies need to put together comprehensive submission packages that include all necessary documentation, such as study protocols and ethical approvals. Engaging with local compliance consultants can further enhance the likelihood of swift approvals, ensuring adherence to ICH-GCP standards and facilitating FDA-bridgeable data acceptance.

    For instance, the Abdala vaccine underwent parallel phase 1/2 evaluations authorized by CECMED, which commenced in December 2020 with 132 volunteers. This efficient approval process allowed the vaccine to progress through subsequent phases, ultimately leading to its Emergency Use Authorization. Similarly, the Soberana 02 vaccine’s studies, which began with 40 participants in November 2020, demonstrated the efficacy and safety of the vaccine in larger populations, highlighting the effectiveness of Cuba’s oversight framework. However, many companies find it challenging to navigate the complexities of these pathways. By comprehending and navigating these pathways, MedTech companies can achieve quicker approvals and expedite their timelines for medtech clinical trial Cuba.

    Additionally, leveraging services like those offered by bioaccess® can further streamline the process. Bioaccess® has effectively supported numerous innovators in Latin America, such as Axoft and Newrotex, in navigating compliance environments and achieving first-in-human studies efficiently. To effectively navigate these regulatory pathways, companies should prioritize early engagement with CECMED and consider local partnerships to streamline the approval process. Without local expertise, companies may face delays that can significantly slow their market entry.

    This flowchart shows the steps companies can take to navigate the regulatory landscape in Cuba for faster medtech clinical trial approvals. Follow the arrows to see how each action leads to the next, helping you understand the process clearly.

    Utilize bioaccess® for Expert Support in Clinical Trials

    Navigating the complexities of medtech clinical trial Cuba can be daunting for MedTech companies, but partnering with bioaccess® provides a strategic advantage. As a specialized Contract Research Organization (CRO), bioaccess® provides exceptional expertise in conducting first-in-human studies, delivering a comprehensive range of services tailored to the unique needs of early-stage studies. These services encompass:

    This ensures a seamless process from initiation to completion.

    With a robust network of over 50 pre-qualified research sites across Latin America, bioaccess® guarantees that studies are conducted efficiently and adhere to ICH-GCP standards. This extensive site network not only accelerates patient recruitment but also increases the likelihood of achieving research milestones within tight timelines. Notably, bioaccess® can secure ethics approvals in as little as 4-8 weeks, providing FDA/EMA-ready data that expedites the overall research process. Their deep understanding of local regulatory environments, including compliance with INVIMA in the region and ANVISA in Brazil, enables bioaccess® to fast-track approvals, often reaching regulatory milestones in just 30-90 days.

    By leveraging bioaccess®’s expertise, MedTech firms can confidently navigate the intricacies of medtech clinical trial Cuba, ensuring that their innovative products reach the market more effectively and efficiently. Embracing this partnership not only streamlines the research process but also positions your company at the forefront of innovation in Latin America.

    This flowchart outlines the key services provided by bioaccess® in the clinical trial process. Each box represents a crucial step that helps MedTech companies navigate their trials effectively. Follow the arrows to see how each service connects and contributes to the overall success of the study.

    Explore Cost Benefits of Conducting Trials in Cuba

    MedTech firms are increasingly turning to Cuba for medtech clinical trials, drawn by the promise of substantial cost savings and expedited processes. Conducting studies here can reduce overall expenses per patient by about 30% compared to the U.S. or EU. Lower operational costs and a streamlined compliance process lead to faster approvals from authorities like INVIMA. This regulatory environment fosters quicker access to study initiation, allowing firms to allocate resources more efficiently, reducing financial strain and accelerating study timelines.

    Additionally, patient recruitment costs decrease for the medtech clinical trial in Cuba because the healthcare system provides access to a diverse and enthusiastic patient population ready to participate in research studies. Adherence to ICH-GCP standards and the potential for FDA approval for data significantly enhance the appeal of conducting studies in this region. By utilizing insights from bioaccess®’s Global Trial Accelerators™, MedTech startups can effectively navigate these advantages, positioning Latin America as a strategic asset for early-stage studies in the MedTech sector.

    Each slice of the pie shows a different aspect of cost savings when conducting trials in Cuba. The larger the slice, the more significant the savings or benefit in that area.

    Implement Effective Patient Recruitment Strategies in Cuba

    Effective patient recruitment strategies are not just beneficial; they are essential for the success of medtech clinical trial Cuba. Local healthcare networks and community outreach initiatives greatly enhance awareness of ongoing studies. Collaborating with local healthcare providers fosters trust, which is crucial for encouraging patient participation. Digital platforms and social media campaigns boost visibility and engagement, allowing for targeted outreach to potential participants based on demographics and interests.

    Incentives such as transportation assistance or health screenings can further encourage individuals to participate in studies. Addressing cultural nuances and concerns about participation is crucial for improving recruitment rates. For example, community-based recruitment strategies have proven effective in attracting a varied participant pool, ensuring that studies are more representative and ethically sound.

    Additionally, integrating with local clinics and pharmacies can enhance recruitment efforts by displaying informative materials and training staff to refer eligible patients. This grassroots method not only fosters trust but also enhances the visibility of the study, making it simpler to recruit participants from diverse backgrounds. Focusing on these strategies not only leads to higher enrollment rates but also significantly advances the medtech clinical trial Cuba in the region.

    Start at the center with the main theme of patient recruitment strategies, then explore each branch to see specific methods and ideas that contribute to successful recruitment in clinical trials.

    Seek Collaboration Opportunities with Local Entities

    Navigating the complexities of medical research in Cuba can be daunting without local partnerships. Partnering with regional organizations, such as universities, hospitals, and research institutions, significantly enhances the efficiency of medical studies. These collaborations provide access to valuable resources, including patient populations, medical expertise, and logistical support. Engaging local stakeholders not only facilitates smoother regulatory interactions but also builds community trust in the study process. Companies must seize every opportunity for collaboration, such as joint research initiatives or educational programs, to cultivate relationships that can enhance their research efforts. Fostering these relationships is not just beneficial; it’s essential for the success of clinical research in the region.

    The central node represents the main theme of collaboration. Each branch shows different aspects of collaboration, such as local entities involved, the benefits gained, and the types of partnerships that can be formed. Follow the branches to understand how these elements connect to enhance medical research.

    Consider Cultural Factors in Clinical Trial Design

    Cultural factors are often the key to unlocking participant engagement and retention in medtech clinical trial Cuba. Understanding local customs, beliefs, and healthcare practices allows for the customization of study protocols that meet participants’ expectations and needs. For instance, employing culturally relevant communication strategies and materials significantly enhances understanding and trust among potential participants.

    A case study showed that involving local community leaders in the recruitment process fostered a sense of ownership, encouraging participation and improving enrollment rates. It’s crucial for companies conducting a medtech clinical trial in Cuba to prioritize cultural competence in their study designs, as it not only builds participant trust but also boosts overall success rates in obtaining approvals from authorities like CECMED.

    Adhering to ICH-GCP standards and leveraging local insights helps sponsors navigate the compliance landscape effectively. Furthermore, grasping the distinctions between First-in-Human (FIH) and Early Feasibility Studies (EFS) is essential; FIH assessments examine a medical device or drug in humans for the first time, while EFS assess design concepts in a limited number of subjects.

    Sponsors must also prepare specific preclinical documentation, including:

    1. Biocompatibility testing
    2. Material characterization
    3. Software validation
    4. Animal studies

    to meet the requirements of ethics committees and regulatory authorities. bioaccess® assists sponsors by arranging this preclinical documentation and overseeing the importation process for investigational devices, ensuring that studies are performed efficiently and in accordance with local regulations.

    This strategic method ultimately results in quicker and more effective studies, leveraging the affordable and accelerated services available in Latin America. Ultimately, neglecting cultural nuances can hinder the success of clinical trials, making cultural competence not just beneficial but essential.

    This mindmap illustrates how cultural factors influence various aspects of clinical trial design. Start at the center with the main theme, then explore how participant engagement, community involvement, and regulatory compliance are interconnected. Each branch represents a key area, with further details that show specific strategies and requirements.

    Adopt Innovative Technologies for Enhanced Trial Efficiency

    In Cuba, the adoption of innovative technologies is essential for enhancing the effectiveness of medtech clinical trial Cuba. Tools such as electronic data capture (EDC) and telemedicine streamline data collection and improve patient monitoring, facilitating real-time access to critical information. These technologies enhance participant engagement and ensure compliance with standards set by authorities like COFEPRIS and ANVISA. For instance, EDC systems can significantly reduce data entry errors and accelerate the data review process, a critical factor for achieving ICH-GCP compliance. Moreover, utilizing telemedicine for patient recruitment and follow-up can reduce timelines and enhance retention rates, ultimately resulting in quicker completion of the study. Companies investing in these technologies can optimize their clinical study processes, ensuring they meet regulatory requirements while achieving high-quality outcomes. With bioaccess®‘s ability to secure ethics approvals in just 4-8 weeks across countries like Panama, El Salvador, and Chile, companies can benefit from:

    By embracing these advancements, companies position themselves not only for compliance but also for substantial financial and operational gains.

    This mindmap illustrates how adopting innovative technologies can improve clinical trial efficiency. Start at the center with the main theme, then explore the branches to see the specific technologies, their benefits, and the financial impacts they can have on clinical trials.

    Anticipate Future Growth Opportunities in Cuba’s MedTech Sector

    Cuba’s MedTech sector stands at a pivotal moment, poised for remarkable growth driven by advancements in biotechnology and a commitment to healthcare innovation. With the modernization of its healthcare infrastructure, Cuba presents MedTech companies with unprecedented opportunities to introduce innovative technologies and products. Key trends to monitor include the rising demand for telehealth solutions and personalized medicine, which are rapidly becoming essential in the Cuban healthcare landscape.

    The Cuban government is taking significant steps to strengthen its oversight framework, which is vital for facilitating clinical studies and fostering collaboration with international partners. Regulatory authorities such as the Cuban Center for State Control of Medicines, Medical Equipment and Devices (CECMED) play a pivotal role in this process, ensuring compliance with international standards like ICH-GCP.

    With bioaccess®’s expertise, companies can expect to navigate the regulatory landscape more efficiently. Bioaccess® achieves ethics/IRB approvals in as little as 4-8 weeks, significantly faster than the 6-12 months typical in the US/EU. This streamlined approval process, combined with the cost efficiency of conducting trials in the region-offering 30% lower expenses compared to the US/EU and per-patient savings of up to $25,000-makes this location an attractive choice for first-in-human trials.

    Strategic planning that aligns with these emerging trends will be crucial for MedTech firms aiming to capitalize on Cuba’s evolving landscape. By strategically aligning with these trends, MedTech firms can not only enter the market successfully but also contribute to the evolution of healthcare in Cuba.

    This mindmap starts with the main theme in the center and branches out to show various opportunities and trends in Cuba's MedTech sector. Each branch represents a key area of focus, and the sub-branches provide more detailed insights into each topic.

    Conclusion

    Navigating Cuba’s MedTech clinical trial landscape offers unparalleled advantages, yet it demands a keen understanding of its regulatory intricacies. This landscape provides unmatched regulatory efficiency, cost advantages, and a diverse patient population, establishing it as a prime destination for early-stage research. Understanding the regulatory framework governed by CECMED is essential for success in this landscape, as it expedites approval timelines while ensuring compliance with international standards. By leveraging local expertise and resources, MedTech companies can effectively navigate these pathways to achieve successful trial outcomes.

    Key arguments discussed include the significance of first-in-human trials, the streamlined approval processes, and the cost benefits associated with conducting studies in Cuba. The country’s commitment to healthcare innovation, combined with its robust infrastructure and patient engagement strategies, enhances the feasibility of clinical research. Furthermore, partnerships with local entities and the adoption of innovative technologies are pivotal in optimizing trial efficiency and participant recruitment.

    As Cuba’s MedTech sector evolves, companies must actively pursue collaboration and innovation to thrive. By aligning with local insights and regulatory requirements, firms can not only accelerate their market entry but also contribute to the advancement of healthcare solutions in the region. By seizing these collaborative opportunities, companies can redefine the future of healthcare in Cuba and beyond.

    Frequently Asked Questions

    What is the role of CECMED in Cuba’s MedTech clinical trials?

    CECMED, the Center for State Control of Medicines, Equipment and Medical Devices, oversees the regulatory system for MedTech research studies in Cuba. It assesses and sanctions medical studies to ensure compliance with international standards like ICH-GCP.

    What is required to initiate a clinical study in Cuba?

    To commence a clinical study in Cuba, applicants must submit a comprehensive dossier that includes preclinical data, ethical approvals, and a detailed study protocol.

    How long does it typically take to receive regulatory approval from CECMED?

    Regulatory approval from CECMED often occurs within 30 to 90 days, which is notably faster than in many other regions.

    How did CECMED adapt its processes during the COVID-19 pandemic?

    During the COVID-19 pandemic, CECMED modified its processes to speed up approvals, allowing for emergency use of vaccines like Abdala based on data from earlier phases of evaluation.

    What advantages does Cuba offer for MedTech clinical trials?

    Cuba provides strategic advantages such as a strong healthcare infrastructure, efficient patient recruitment, cost efficiency, and a regulatory framework that facilitates faster approvals.

    Why are first-in-human (FIH) trials important in Cuba?

    FIH trials are crucial in Cuba due to the country’s strong healthcare infrastructure and skilled clinical workforce, which enhance the safety and efficacy assessments of MedTech innovations.

    How can MedTech companies benefit from conducting trials in Cuba?

    Conducting trials in Cuba can lead to accelerated market entry, improved funding opportunities, and enhanced data quality due to the diverse patient population.

    What support can MedTech companies seek to navigate the regulatory landscape in Cuba?

    MedTech companies can engage local compliance consultants and seek partnerships to enhance their understanding of the regulatory pathways, ensuring adherence to ICH-GCP standards and facilitating FDA-bridgeable data acceptance.

    Can you provide examples of successful studies conducted in Cuba?

    The Abdala vaccine underwent parallel phase 1/2 evaluations authorized by CECMED, leading to its Emergency Use Authorization, while the Soberana 02 vaccine demonstrated efficacy and safety in larger populations during its studies.

    What should companies prioritize to achieve quicker approvals in Cuba?

    Companies should prioritize early engagement with CECMED and consider local partnerships to streamline the approval process and avoid delays that can slow market entry.

    List of Sources

    1. Understand Cuba’s Regulatory Landscape for MedTech Trials
      • scielosp.org (https://scielosp.org/article/medicc/2021.v23n3-4/9-14)
    2. Recognize the Importance of First-in-Human Trials in Cuba
      • First-In-Human Clinical Trial Requirement -BioPharma Services (https://biopharmaservices.com/blog/phase-1-which-requirements-must-be-met-to-conduct-first-in-human-clinical-trials)
      • New York Times Article on Clinical Trials Features Quote from the Alliance for Aging Research – Alliance for Aging Research (https://agingresearch.org/blog/new-york-times-article-on-clinical-trials-features-quote-from-the-alliance-for-aging-research)
    3. Leverage Streamlined Regulatory Pathways for Faster Approvals
      • scielosp.org (https://scielosp.org/article/medicc/2021.v23n3-4/9-14)
    4. Utilize bioaccess® for Expert Support in Clinical Trials
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • patentpc.com (https://patentpc.com/blog/clinical-trial-success-rates-how-many-drugs-make-it-to-market-latest-approval-stats)
      • Latin America Clinical Trials Market Size & Outlook, 2033 (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/latin-america)
    5. Explore Cost Benefits of Conducting Trials in Cuba
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC12311479)
      • ccrps.org (https://ccrps.org/clinical-research-blog/ranking-top-countries-for-clinical-trials-2026-comprehensive-report)
      • New York Times Article on Clinical Trials Features Quote from the Alliance for Aging Research – Alliance for Aging Research (https://agingresearch.org/blog/new-york-times-article-on-clinical-trials-features-quote-from-the-alliance-for-aging-research)
      • The Ultimate Guide to Clinical Trial Costs in 2025 (https://sofpromed.com/ultimate-guide-clinical-trial-costs)
    6. Implement Effective Patient Recruitment Strategies in Cuba
      • Patient Recruitment Strategies for Trials | CCRPS (https://ccrps.org/clinical-research-blog/patient-recruitment-strategies-for-clinical-trials)
      • New York Times Article on Clinical Trials Features Quote from the Alliance for Aging Research – Alliance for Aging Research (https://agingresearch.org/blog/new-york-times-article-on-clinical-trials-features-quote-from-the-alliance-for-aging-research)
      • Community-Based Patient Recruitment in Latin America – H Clinical (https://hclinical.com/community-based-patient-recruitment-for-clinical-trials-in-latin-america)
    7. Consider Cultural Factors in Clinical Trial Design
      • clinicalleader.com (https://clinicalleader.com/doc/how-cultural-competency-can-increase-clinical-trial-diversity-0001)
      • signanthealth.com (https://signanthealth.com/resources/blog/cultural-competence-and-cultural-humility-in-clinical-trials-1)
      • appliedclinicaltrialsonline.com (https://appliedclinicaltrialsonline.com/view/multinational-clinical-trials-breaking-language-and-cultural-barriers)
    8. Adopt Innovative Technologies for Enhanced Trial Efficiency
      • 70 Research Quotes to Inspire Your Work – Qualtrics (https://qualtrics.com/articles/strategy-research/research-quotes)
    9. Anticipate Future Growth Opportunities in Cuba’s MedTech Sector
    • patentpc.com (https://patentpc.com/blog/medtech-industry-growth-latest-market-stats)

  • 4 LATAM Post-Pandemic Medtech Opportunities to Accelerate Trials

    4 LATAM Post-Pandemic Medtech Opportunities to Accelerate Trials

    Introduction

    The medical technology landscape in Latin America is experiencing a significant shift, driven by an urgent need for innovation and efficiency in clinical trials. Companies are eager to seize post-pandemic opportunities, and this region offers a compelling mix of cost-effectiveness, streamlined regulatory processes, and a diverse patient population. However, the complexities of differing regulations and market dynamics present notable challenges.

    What strategies can stakeholders implement to harness these advantages while navigating potential obstacles in this rapidly evolving market?

    bioaccess: Accelerate Clinical Trials in Latin America

    bioaccess® presents a highly in Latin America, significantly . With a robust network of over 50 pre-qualified research locations, bioaccess® ensures that studies can commence promptly, often securing ethics approvals in just . This rapid initiation is further bolstered by a that enrolls participants , all while maintaining a cost structure approximately 30% lower than similar studies in North America or Western Europe.

    , recognized as one of the best globally, enhances these efficiencies, making it an ideal hub for Medtech and biopharma companies eager to pursue in the expanding market. Moreover, the overall evaluation process by the IRB/EC and MoH (INVIMA) in Colombia typically spans 90 to 120 days, which further elevates the attractiveness of conducting in this region.

    In summary, the collaboration between bioaccess® and clinical research entities not only but also positions stakeholders to leverage the .

    Each box represents a step in the clinical trial process. Follow the arrows to see how quickly bioaccess® can move from ethics clearance to patient enrollment and study commencement.

    Leverage Cost-Effective Clinical Trials in Latin America

    offers remarkable , with expenses typically ranging from 30% to 75% lower than those in the U.S. or Western Europe. This significant reduction is achieved without compromising quality, thanks to and a favorable legal environment. For example, can lead to approvals in as little as 90-120 days, significantly expediting timelines.

    • including feasibility assessments, site selection, compliance evaluations, setup, and project management – further enhance these efficiencies. These savings empower companies to reinvest in research and development, strengthening their . Moreover, the region’s , facilitating and more comprehensive data collection. This ultimately drives down costs while ensuring high-quality research outcomes.

    Collaborations, such as the one between bioaccess and Caribbean Health Group, position Barranquilla as a key hub for medical research in Latin America, showcasing the supported by Colombia’s Minister of Health. This partnership exemplifies how strategic alliances can amplify the benefits of conducting clinical trials in this region, paving the way for innovative solutions in the Medtech landscape and highlighting the .

    Each segment shows how much lower the costs are in Latin America compared to the U.S. and Western Europe. The larger the segment, the greater the savings, highlighting the benefits of conducting trials in this region.

    Capitalize on the Dominican Republic’s Medtech Hub

    The Dominican Republic is swiftly emerging as a pivotal player in the , thanks to its strategic geographic position and favorable manufacturing conditions. This surge in medical device manufacturers is supported by a government framework that encourages investment and innovation. As a result, , facilitating easier access to both local and regional markets.

    The country boasts a strong healthcare system, complemented by that enable effective cooperation on . Notably, the Dominican administration has invested over $1.580 billion since 2013 in modern infrastructure, significantly enhancing the nation’s appeal for Medtech companies eager to conduct research. bioaccess® plays a crucial role in this landscape, offering extensive research study management services, including:

    This ensures that studies are executed with high expertise and adaptability.

    As industry specialists note, the Dominican Republic’s and efforts to enhance access to healthcare services are key LATAM post-pandemic Medtech opportunities for companies aiming to speed up their studies. With established , the Dominican Republic not only simplifies market access but also fosters a competitive environment for medical device production. This makes it an optimal site for accelerating research and contributing to economic development through job creation and improved healthcare services.

    The central node represents the Medtech hub, while branches show key areas of focus. Each sub-branch provides specific details, helping you understand how the Dominican Republic is positioning itself in the Medtech sector.

    Navigate Regulatory Frameworks for Successful Market Entry

    Successfully entering the Latin American market demands a deep understanding of the diverse legal frameworks that vary across countries. Each nation, from Brazil to Mexico, has its own regulations governing . Companies must engage with , such as ANVISA in Brazil and COFEPRIS in Mexico, to ensure compliance and streamline the validation process.

    Bioaccess® stands out by delivering accelerated , including and trial data management. This , Biopharma, and Radiopharma startups as they . Statistics reveal that government consent and reimbursement durations in countries like Colombia, Chile, and Mexico often exceed the regional average of 4.75 years, with patients waiting an to access innovative therapies post-clearance. Furthermore, 61% of internationally approved medicines have received in at least one Latin American country.

    By leveraging local expertise and the comprehensive services offered by bioaccess®, companies can navigate these challenges more effectively. This approach not only reduces time to market but also enhances their chances of success in this burgeoning market. Collaboration with local entities is essential for overcoming obstacles and achieving favorable outcomes in .

    The central node represents the main theme, while branches show different aspects of market entry, including specific countries and their regulations. Each color-coded branch helps you easily identify related topics.

    Conclusion

    The opportunities for Medtech companies in Latin America post-pandemic are not just plentiful; they are strategically advantageous. By leveraging the region’s unique strengths – such as rapid ethics clearance, cost-effective trial execution, and a diverse patient population – stakeholders can significantly enhance their clinical research outcomes while simultaneously reducing costs. The collaboration between innovative platforms like bioaccess® and local healthcare systems exemplifies the potential for accelerated trials, positioning Latin America as a prime landscape for Medtech advancements.

    Key insights from the article underscore the impressive efficiencies that come with conducting clinical trials in Latin America. With timelines for ethics approvals reduced to mere weeks and costs slashed by up to 75% compared to the U.S. and Western Europe, the region stands out as a competitive player in the global Medtech arena. The Dominican Republic’s emergence as a Medtech hub, bolstered by government support and investment in healthcare infrastructure, further highlights the region’s potential for growth and innovation.

    As the Medtech landscape continues to evolve, it is crucial for companies to seize these opportunities and navigate the regulatory complexities inherent in the region. By forming strategic partnerships and leveraging local expertise, businesses can not only accelerate their market entry but also contribute to the overall enhancement of healthcare services in Latin America. Engaging with this dynamic market will drive innovation and foster economic development, ultimately leading to improved patient outcomes across the region.

    Frequently Asked Questions

    What is bioaccess® and what does it offer for clinical trials in Latin America?

    bioaccess® presents a highly efficient method for conducting clinical studies in Latin America, significantly reducing timelines for ethics clearances and patient enrollment.

    How quickly can ethics approvals be secured through bioaccess®?

    Ethics approvals can often be secured in just 4 to 8 weeks.

    How does bioaccess® improve patient recruitment for clinical trials?

    bioaccess® employs a patient recruitment strategy that enrolls participants 40% faster than traditional US or EU schedules.

    What cost advantages does bioaccess® provide compared to studies in North America or Western Europe?

    The cost structure of studies conducted through bioaccess® is approximately 30% lower than similar studies in North America or Western Europe.

    Why is Colombia considered an ideal location for conducting clinical trials?

    Colombia’s healthcare system is recognized as one of the best globally, enhancing efficiencies and making it an attractive hub for Medtech and biopharma companies.

    What is the typical timeline for the overall evaluation process by the IRB/EC and MoH (INVIMA) in Colombia?

    The overall evaluation process typically spans 90 to 120 days.

    How does bioaccess® position stakeholders for post-pandemic opportunities in Latin America?

    The collaboration between bioaccess® and clinical research entities streamlines processes, allowing stakeholders to leverage the expanding LATAM post-pandemic medtech opportunities.

    List of Sources

    1. bioaccess: Accelerate Clinical Trials in Latin America
      • Latin America the ‘Hidden Gem’ for First-in-Human Medical Device Trials (https://clinicalresearchnewsonline.com/news/2025/08/14/latin-america-the-hidden-gem-for-first-in-human-medical-device-trials)
      • linkedin.com (https://linkedin.com/pulse/latin-america-clinical-trials-boom-462b-2025-794b-2034-iaqhc)
      • statista.com (https://statista.com/statistics/1013599/latin-america-clinical-trials?srsltid=AfmBOoqBVl-xi0J7jcZ8gIQYCpSPxkKfZOi-7AMHTD8BJxbNnt623c3R)
      • Why Latin America Leads In Clinical Trials Exploring The Key Factors | bioaccess® (https://bioaccessla.com/blog/why-latin-america-leads-in-clinical-trials-exploring-the-key-factors)
      • juliomartinezclark.com (https://juliomartinezclark.com/blog/first-in-human-clinical-trials-latin-america-complete-guide)
    2. Leverage Cost-Effective Clinical Trials in Latin America
      • Latin America Clinical Trials Market Size & Outlook, 2033 (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/latin-america)
      • linkedin.com (https://linkedin.com/pulse/latin-america-clinical-trials-boom-462b-2025-794b-2034-iaqhc)
      • bioaccessla.com (https://bioaccessla.com/blog/the-latin-american-advantage-why-clinical-trial-recruitment-and-retention-outpace-the-us-and-europe)
      • towardshealthcare.com (https://towardshealthcare.com/insights/latin-america-clinical-trials-market-sizing)
      • 7 Reasons Why Latin America is the Emerging Clinical Research Region | bioaccess® (https://bioaccessla.com/blog/7-reasons-why-latin-america-is-the-emerging-clinical-research-region)
    3. Capitalize on the Dominican Republic’s Medtech Hub
      • medical-technology.nridigital.com (https://medical-technology.nridigital.com/medical_technology_sep25/precision_in_paradise_the_dominican_republic_emerges_as_latin_america_s_medtech_hub)
      • statista.com (https://statista.com/outlook/hmo/medical-technology/dominican-republic?srsltid=AfmBOopVVHr3mzU3ozfJoVn5w2NQOaeZXNtfO4d-AxXo4JwuUaQDrC46)
      • statista.com (https://statista.com/outlook/hmo/medical-technology/medical-devices/dominican-republic?srsltid=AfmBOopWD6fmWk518lTdXQ8MkCyDh6yPT4EHuK3v-XervwLxE5nYfYJx)
      • morningstar.com (https://morningstar.com/news/accesswire/1127464msn/how-the-dominican-republic-became-a-quiet-giant-in-medtech-manufacturing-and-what-comes-next-at-caucedo)
    4. Navigate Regulatory Frameworks for Successful Market Entry
      • goodreads.com (https://goodreads.com/quotes/tag/market-entry-strategies)
      • linkedin.com (https://linkedin.com/pulse/latin-america-patch-type-medical-devices-market-size-2026-ndamf)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/medical-device-contract-research-organization-market/latin-america)
      • fifarma.org (https://fifarma.org/en/waitindicator2024)

  • 10 Reasons Costa Rica is Ideal for MedTech Clinical Trials

    10 Reasons Costa Rica is Ideal for MedTech Clinical Trials

    Introduction

    While Costa Rica offers a promising landscape for MedTech clinical trials, the path to success is fraught with challenges that require strategic navigation. This Central American nation boasts a unique blend of favorable regulatory frameworks and a highly skilled workforce, making it an attractive destination for startups eager to accelerate their first-in-human studies. However, navigating the complexities of clinical trials can be daunting for MedTech companies. By effectively leveraging these advantages, companies can position themselves for success in a competitive landscape.

    bioaccess®: Pioneering First-in-Human Trials in Costa Rica

    In a landscape where regulatory challenges can stifle innovation, bioaccess® emerges as a beacon for MedTech and Biopharma startups. With the support of Costa Rica’s favorable regulatory environment and a skilled workforce, bioaccess® has established itself as a leader in conducting first-in-human studies within the framework of a medtech clinical trial in Costa Rica. The Costa Rican Ministry of Health ensures an efficient approval process, crucial for startups looking to accelerate their development. With an average approval timeline of just 30 to 60 days, bioaccess® allows sponsors to concentrate on innovation rather than getting bogged down by regulatory hurdles.

    The organization adheres to ICH-GCP standards. It also guarantees FDA-bridgeable data acceptance, which is vital for sponsors facing the complexities of early-stage studies. By focusing on high-quality data, we enhance study credibility and speed up the path to regulatory approval, both locally and internationally. Leveraging its extensive network of pre-qualified research sites, bioaccess® ensures effective study execution, enabling startups to confidently reach their first-in-human milestones.

    Looking ahead to 2026, Costa Rica is set to host a significant number of medtech clinical trial studies, highlighting the growing interest in the region as a prime research site. Successful studies conducted by bioaccess® and other local CROs have proven the effectiveness of this approach, demonstrating rapid patient recruitment and lower operational costs compared to traditional markets. This strategic advantage positions bioaccess® as the ideal partner for startups eager to navigate the research landscape effectively.

    As the region gears up for a surge in first-in-human studies, aligning with bioaccess® could be the strategic move that propels your startup ahead of the competition.

    This mindmap illustrates how bioaccess® supports MedTech and Biopharma startups in Costa Rica. Each branch represents a key theme, showing how they contribute to the overall goal of facilitating first-in-human studies. Follow the branches to see the connections between regulatory support, operational efficiencies, and future growth opportunities.

    Favorable Regulatory Framework for MedTech Innovations

    Costa Rica stands out as a prime destination for a medtech clinical trial, thanks to its robust regulatory framework overseen by the Ministry of Health and the National Health Research Council (CONIS). The approval process for studies typically spans from 30 to 90 days, significantly outpacing many other regions. This efficiency, bolstered by adherence to international standards like ICH-GCP, guarantees that all studies uphold the highest ethical and scientific benchmarks. The streamlined regulatory process enables swift commencement of studies, thereby shortening time to market and enhancing the practicality of research. Moreover, the nation’s dedication to upholding high compliance standards ensures that sponsors can navigate the regulatory environment effectively, establishing it as a premier hub for medtech clinical trial in Costa Rica and pioneering initial human studies.

    This flowchart illustrates the steps involved in getting approval for medtech clinical trials in Costa Rica. Each box represents a stage in the process, and the arrows show the flow from one step to the next. If a proposal doesn't meet compliance standards, it loops back for revisions, ensuring that all trials adhere to high ethical and scientific benchmarks.

    Access to a Skilled Workforce for Clinical Research

    This Central American nation boasts a highly skilled and bilingual workforce, particularly in medicine, biotechnology, and research, making it an ideal spot for a medtech clinical trial in Costa Rica. The skilled workforce in this nation plays a crucial role in conducting high-quality research, especially in specialized areas like radiopharmaceuticals and theranostics, where bioaccess® leads the way.

    Bioaccess® offers comprehensive regulatory consulting services, equipping research teams to navigate complex protocols and meet the stringent requirements of authorities like INVIMA and ANVISA, while ensuring compliance with ICH-GCP standards. Furthermore, established training programs and certifications enhance the capabilities of local professionals, making them valuable assets for international sponsors.

    Navigating the complex regulatory landscape can be daunting for research teams, often leading to delays and compliance issues. However, with bioaccess®’s expertise, these challenges can be effectively managed, leading to smoother project execution. Thanks to bioaccess®’s expertise, this Central American nation emerges as a premier destination for accelerating early-stage studies, ensuring compliance, and enhancing patient recruitment efficiency.

    The central node represents the overall theme of the skilled workforce. Each branch shows a key area of focus, and the sub-branches detail specific elements within those areas. This layout helps you understand how each part contributes to the strength of clinical research in Costa Rica.

    Cost-Effective Clinical Trial Execution

    Startups in clinical research find that medtech clinical trial Costa Rica presents a more attractive alternative due to the daunting costs in the U.S. and Europe. Conducting a medtech clinical trial Costa Rica presents significant cost benefits compared to these traditional markets, with potential reductions in trial expenses of up to 30%. This cost-effectiveness comes from lower operational expenses and competitive investigator fees. For startups aiming to conserve capital while generating essential trial data, medtech clinical trial Costa Rica makes the region an appealing choice. For instance, the average healthcare spending per person in the U.S. reached $13,432 in 2023, highlighting the stark contrast with Costa Rica’s more affordable healthcare landscape.

    Additionally, bioaccess® boosts these savings through its Innovation Runway, the world’s first development pathway designed exclusively for First-in-Human (FIH) studies. This innovative method helps MedTech, Biopharma, and Radiopharma startups move from prototype to key milestones 40% faster, ensuring they can secure funds, attract strategic acquirers, and achieve their exit before resources deplete. Streamlined management processes ensure compliance with ICH-GCP standards and facilitate FDA-bridgeable data acceptance. Regulatory bodies like INVIMA in the region create a supportive setting for the medtech clinical trial Costa Rica, with approval timelines frequently quicker than in the U.S. Startups can access essential human data faster, allowing them to navigate submission pathways efficiently. By leveraging these advantages, startups can not only reduce costs but also expedite their journey toward regulatory approval and market entry. Failing to leverage these advantages could lead to prolonged timelines and increased costs, jeopardizing their success. Testimonials from clients who have successfully conducted medtech clinical trial Costa Rica further highlight the operational efficiencies and cost savings attainable in this area.

    This pie chart shows how much it costs to conduct clinical trials in the U.S. compared to the savings you can achieve in Costa Rica. The larger slice represents the higher spending in the U.S., while the smaller slice shows the significant savings available in Costa Rica.

    Strategic Location for Market Access

    Positioned at the crossroads of North and South America, this nation emerges as a pivotal hub for MedTech companies seeking to expand their reach. The country boasts direct access to major trade routes, supported by a robust logistics infrastructure that facilitates efficient distribution of medical devices across the Americas. It participates in over 15 free trade agreements. These agreements enhance market access and reduce tariffs on medical devices, simplifying entry for companies.

    For instance, the medical device industry in this Central American nation has seen significant expansion, with exports hitting $7.6 billion by 2023, underscoring its status as a top exporter in this sector. Companies like Boston Scientific leverage the region’s strategic location to optimize their supply chains and strengthen their market presence. Additionally, the establishment of free trade zones allows for the importation of raw materials without incurring duties or taxes, further lowering operational costs for early-stage studies.

    Conducting a medtech clinical trial in Costa Rica not only positions companies favorably for future market entry but also aligns with the expedited regulatory pathways available in the region. Regulatory bodies, such as the Ministry of Health, oversee approval for research studies, and adherence to ICH-GCP standards is crucial for effective execution. With a commitment to FDA-bridgeable data acceptance, bioaccess® ensures that studies are conducted efficiently, enabling sponsors to secure regulatory approvals in as few as 30-90 days. These logistical benefits and regulatory efficiencies position this Central American nation as an ideal choice for MedTech early feasibility studies.

    This mindmap shows how the country's strategic location benefits MedTech companies. Each branch represents a key area: geographical advantages, trade agreements, export growth, and regulatory benefits. Follow the branches to see how these elements work together to create a favorable environment for market access.

    Thriving MedTech Ecosystem and Collaboration Opportunities

    In a rapidly evolving MedTech landscape, Central America stands out as a hub of innovation and collaboration. The Central American nation showcases a strong MedTech ecosystem, hosting over 90 multinational companies and a vibrant range of startups. This environment fosters collaboration among industry stakeholders. Research institutions and government agencies form a rich network that drives innovation. Companies can tap into partnerships that facilitate resource sharing, knowledge exchange, and access to advanced technologies. Significantly, events such as the MPO MedTech Forum act as essential venues for networking and collaboration, improving the chances for successful studies and product development.

    The medical device industry in the Central American nation has experienced significant growth, with exports reaching $9.199 billion by October 2025, indicating a year-on-year rise of 30%. With over 60,000 skilled professionals directly employed in the medical device industry, this growth is backed by a robust workforce, and an expected annual increase of approximately 5,000 jobs due to new investments. Moreover, the strategic position of the nation and advantageous regulatory framework, including adherence to ICH-GCP standards and FDA-bridgeable data acceptance, facilitate the process of early-stage research. However, navigating the complex regulatory landscape can be daunting for new entrants.

    Multinational companies operating in Costa Rica, such as Boston Scientific and Hologic, contribute significantly to the local ecosystem by engaging in research and development activities. This partnership not only improves the quality of medical research but also encourages innovation through the closeness of specialized suppliers and advanced manufacturing capabilities. As Laura López, CEO of PROCOMER, emphasizes, ‘The proximity of these companies to local suppliers not only fosters innovation but also enhances the quality of medical studies.’ As the nation continues to draw foreign direct investment, the MedTech sector is set for further growth, establishing it as an ideal site for conducting medtech clinical trials in Costa Rica, including first-in-human studies. Moreover, bioaccess® plays a crucial role in this environment, utilizing its Innovation Runway to expedite development for MedTech, Biopharma, and Radiopharma startups, ensuring they navigate regulatory challenges effectively and achieve milestones more rapidly. As the MedTech sector flourishes, the potential for groundbreaking advancements in clinical research becomes increasingly attainable.

    This mindmap illustrates the interconnected components of the MedTech ecosystem in Central America. Start at the center with the main theme, then explore the branches to see how multinational companies, startups, research institutions, and government agencies contribute to innovation and collaboration in the industry.

    Commitment to Patient Safety and Ethical Standards

    In an era where patient safety is paramount, the nation’s commitment to ethical research practices stands as a beacon of trust in clinical trials. The country’s regulatory framework, including Law 9234, emphasizes the protection of human subjects and mandates rigorous ethical review processes. Navigating the complex regulatory landscape can be daunting for researchers, yet it is essential for ensuring patient safety.

    All research studies must receive approval from an Institutional Review Board (IRB) to guarantee adherence to ethical guidelines. However, this commitment ultimately strengthens the integrity of clinical research in the nation. By prioritizing ethical standards, we not only protect participants but also elevate the entire field of clinical research, paving the way for groundbreaking advancements.

    The center represents our commitment to safety and ethics in research. Each branch shows different aspects of this commitment, like laws and review processes, helping you see how they all connect to protect patients and improve research.

    Government Support for Healthcare Innovation

    In a landscape where healthcare innovation is paramount, the government’s initiatives are reshaping the MedTech sector. Actively promoting healthcare innovation, the government has launched a variety of initiatives aimed at attracting foreign investment in MedTech. Key among these are the tax benefits available to companies operating within free trade zones, which include exemptions from income tax, VAT, and tariffs. These incentives significantly lower operational costs for study sponsors. As a result, conducting research in the region becomes more financially viable.

    In addition to tax advantages, the government has streamlined regulatory approval processes, ensuring that companies can navigate the complexities of compliance efficiently. For instance, medical studies performed in the Central American nation must comply with ICH-GCP standards, and the country provides FDA-bridgeable data acceptance, promoting smoother pathways for submissions to regulatory bodies such as INVIMA and ANVISA. Navigating the regulatory landscape can be daunting for many companies, but these improvements make it easier.

    With a strong commitment to improving healthcare infrastructure and workforce, the nation solidifies its competitive edge in clinical research. Having over 90 MedTech multinationals and a skilled workforce means companies can tap into the resources and expertise needed for successful studies. This supportive environment not only enhances operational efficiency for sponsors but also contributes to the overall growth and innovation within the MedTech industry in the region. As these developments unfold, the potential for groundbreaking advancements in clinical research becomes increasingly tangible.

    The central node represents the overall theme of government support. Each branch highlights a key area of focus, with sub-branches detailing specific initiatives or benefits. This structure helps you see how different aspects of government support interconnect and contribute to the growth of the MedTech sector.

    Advanced Infrastructure for Clinical Trials

    In the competitive landscape of clinical research, medtech clinical trial Costa Rica stands out as a beacon of efficiency and innovation. The country is equipped with advanced infrastructure that significantly enhances the execution of medical research. It boasts state-of-the-art research facilities, a robust transportation network, and access to cutting-edge technology. Its healthcare system is highly regarded, with numerous hospitals and clinics accredited by international standards, ensuring compliance with ICH-GCP guidelines and facilitating FDA-bridgeable data acceptance. Regulatory bodies such as INVIMA, ANVISA, and COFEPRIS play a vital role in supervising research studies, ensuring that all investigations meet rigorous compliance standards.

    Long approval timelines in the US and EU can hinder timely research progress. In contrast, Costa Rica provides expedited regulatory pathways, with approval timelines ranging from 4 to 8 weeks-much quicker than the 6+ months usually observed in those regions. This means that companies can bring their innovations to market more quickly. This infrastructure optimizes study operations. It also ensures participants receive high-quality care during research. For MedTech companies, the successful development of innovative products relies heavily on specialized facilities, especially during a medtech clinical trial Costa Rica.

    Furthermore, the cost savings associated with pre-negotiated site contracts-averaging $25K per patient-allow companies to preserve equity and extend their runway. This enables them to invest savings into R&D or their next funding milestone. Costa Rica’s strategic location in Latin America enhances patient recruitment, making it a prime spot for early-stage studies. By leveraging Costa Rica’s advantages, MedTech companies can accelerate their research and development efforts through a medtech clinical trial Costa Rica, ultimately leading to groundbreaking advancements in healthcare.

    This mindmap illustrates how different elements of Costa Rica's infrastructure contribute to efficient clinical trials. Start at the center with the main theme, then explore each branch to see how facilities, regulations, and costs interact to create a favorable environment for medical research.

    Rapid Patient Recruitment Capabilities

    Costa Rica’s unique demographic and urban landscape positions it as a leader in rapid patient recruitment for medtech clinical trial Costa Rica. With a population of approximately 5 million, the majority of Costa Ricans reside in urban areas, facilitating easier access to potential participants. The nation’s healthcare system, which is highly esteemed and ranked among the finest in Latin America, enhances public trust and engagement in the medtech clinical trial Costa Rica initiatives. By 2026, the average duration for patient recruitment in clinical studies is expected to be notably efficient, with many investigations achieving enrollment targets ahead of schedule.

    bioaccess® strategically engages patients through innovative methods, such as utilizing local healthcare networks and community outreach programs, ensuring that studies are initiated quickly and efficiently. Recent studies have demonstrated swift patient enrollment, with some research reaching their recruitment targets within weeks instead of months. This rapid recruitment in the medtech clinical trial Costa Rica not only speeds up timelines but also enables sponsors to achieve their objectives without unnecessary delays. Furthermore, the strong doctor-patient relationships in Costa Rica contribute to lower dropout rates, thereby enhancing the overall success of the medtech clinical trial Costa Rica has conducted in the region. This efficiency not only accelerates research timelines but also sets a benchmark for clinical trials globally.

    This flowchart illustrates how various factors contribute to the rapid recruitment of patients for clinical trials in Costa Rica. Follow the arrows to see how demographics, healthcare quality, and engagement strategies work together to achieve quick enrollment.

    Conclusion

    Costa Rica stands out as a leading hub for MedTech clinical trials, particularly for first-in-human studies, due to its unique advantages. The nation boasts a favorable regulatory environment, a skilled workforce, and cost-effective execution, making it an ideal choice for startups eager to accelerate their research and development efforts.

    Costa Rica offers a wealth of advantages for conducting clinical trials, making it an attractive option for MedTech companies. With rapid approval timelines of 30 to 90 days, a bilingual and highly trained workforce, and significant cost savings of up to 30% compared to traditional markets, the benefits are clear. Additionally, the country’s strategic location and robust infrastructure facilitate efficient distribution and patient recruitment, ensuring that trials are conducted effectively and ethically. The collaborative MedTech ecosystem fosters partnerships and innovation, further enhancing the region’s attractiveness for clinical research.

    As clinical trials evolve, companies must leverage Costa Rica’s unique benefits to stay ahead. For those navigating the complexities of early-stage studies, aligning with local experts like bioaccess® can streamline processes and enhance the feasibility of groundbreaking advancements in healthcare. By seizing these opportunities, companies can not only enhance their research outcomes but also play a pivotal role in shaping the future of healthcare in Latin America.

    Frequently Asked Questions

    What is bioaccess® and what role does it play in clinical trials in Costa Rica?

    bioaccess® is a specialized contract research organization that conducts first-in-human studies within the framework of medtech clinical trials in Costa Rica. It leverages the country’s favorable regulatory environment and skilled workforce to support MedTech and Biopharma startups in accelerating their development.

    How does the regulatory environment in Costa Rica benefit clinical trials?

    The regulatory environment in Costa Rica is overseen by the Ministry of Health and the National Health Research Council (CONIS), allowing for an efficient approval process that typically spans from 30 to 90 days. This efficiency, combined with adherence to international standards like ICH-GCP, facilitates swift commencement of studies and reduces time to market.

    What are the advantages of conducting studies with bioaccess®?

    bioaccess® provides FDA-bridgeable data acceptance and focuses on high-quality data, enhancing study credibility and speeding up the path to regulatory approval. Additionally, it has an extensive network of pre-qualified research sites, ensuring effective study execution and rapid patient recruitment.

    What compliance standards does bioaccess® adhere to?

    bioaccess® adheres to ICH-GCP standards, ensuring that all studies meet the highest ethical and scientific benchmarks. This compliance is crucial for sponsors navigating the complexities of early-stage studies.

    How does Costa Rica’s workforce contribute to clinical research?

    Costa Rica boasts a highly skilled and bilingual workforce, particularly in medicine, biotechnology, and research. This skilled workforce is essential for conducting high-quality research, especially in specialized areas like radiopharmaceuticals and theranostics.

    What additional support does bioaccess® offer to research teams?

    bioaccess® provides comprehensive regulatory consulting services to help research teams navigate complex protocols and meet the stringent requirements of authorities like INVIMA and ANVISA. This support ensures compliance with ICH-GCP standards and enhances project execution.

    What is the projected future for medtech clinical trials in Costa Rica?

    By 2026, Costa Rica is expected to host a significant number of medtech clinical trial studies, reflecting growing interest in the region as a prime research site. Successful studies conducted by bioaccess® and other local CROs have demonstrated rapid patient recruitment and lower operational costs compared to traditional markets.

    Why should startups consider partnering with bioaccess® for their clinical trials?

    Partnering with bioaccess® provides startups with strategic advantages in navigating the research landscape effectively, including faster approval timelines, high-quality data generation, and access to a skilled workforce, positioning them ahead of the competition in first-in-human studies.

    List of Sources

    1. bioaccess®: Pioneering First-in-Human Trials in Costa Rica
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • Number of clinical trials by year, country, region and income group (https://who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-clinical-trials-by-year-country-who-region-and-income-group)
      • statista.com (https://statista.com/statistics/1249029/clinical-trials-started-worldwide-by-region?srsltid=AfmBOop4rrxqq07m0lMu443-FnvgKnLYq5fh5dOaXpCpa5DNlaykzGm1)
      • clinicaltrials.gov (https://clinicaltrials.gov/about-site/trends-charts)
    2. Favorable Regulatory Framework for MedTech Innovations
      • 7 quotes from 2023 to guide you on the medtech market (https://tiinatyni.com/blogi/7-quotes-from-2023-to-guide-you-on-the-medtech-market)
      • Clinical Trial Regulatory Approval Latin America: 4 Proven Timelines (https://fomatmedical.com/blogs-updates/clinical-trial-regulatory-approval-latin-america)
      • Best Practices for First in Human Trials in Costa Rica | bioaccess® (https://bioaccessla.com/blog/best-practices-for-first-in-human-trials-in-costa-rica)
      • veraqueconsulting.com (https://veraqueconsulting.com/cr/guides/ultimate-guide-for-regulatory-affairs-in-costa-rica)
    3. Cost-Effective Clinical Trial Execution
      • estersplace.com (https://estersplace.com/medical-treatment-costs-usa-vs-costa-rica)
      • ups.com (https://ups.com/cr/en/healthcare/learning-center/blog/rethinking-clinical-trials)
      • unitedlanguagegroup.com (https://unitedlanguagegroup.com/blog/global-news/latin-america-clinical-trials)
    4. Strategic Location for Market Access
      • mddionline.com (https://mddionline.com/manufacturing/why-medtech-is-still-choosing-costa-rica)
      • ticotimes.net (https://ticotimes.net/2025/12/11/costa-ricas-medical-devices-lead-2025-exports)
      • wits.worldbank.org (https://wits.worldbank.org/CountryProfile/en/CRI)
      • wipo.int (https://wipo.int/en/web/global-health/w/news/2024/costa-rica-s-medical-device-revolution)
    5. Thriving MedTech Ecosystem and Collaboration Opportunities
      • ticotimes.net (https://ticotimes.net/2025/12/11/costa-ricas-medical-devices-lead-2025-exports)
      • thecostaricanews.com (https://thecostaricanews.com/costa-rica-consolidates-its-position-as-the-tenth-largest-global-exporter-of-medical-devices)
      • esteri.it (https://esteri.it/en/sala_stampa/archivionotizie/diplomazia-economica/2025/05/il-settore-dei-dispositivi-medici-e-di-precisione-in-costa-rica-crescita-ed-esportazioni-record)
      • mddionline.com (https://mddionline.com/business/why-costa-rica-has-become-a-global-hotbed-for-medical-device-manufacturing)
    6. Government Support for Healthcare Innovation
      • orthospinenews.com (https://orthospinenews.com/2026/01/02/costa-rica-strengthens-its-global-leadership-in-medical-devices-exporting-innovation-to-the-world)
      • taxsummaries.pwc.com (https://taxsummaries.pwc.com/costa-rica/corporate/tax-credits-and-incentives)
      • wipo.int (https://wipo.int/en/web/global-health/w/news/2024/costa-rica-s-medical-device-revolution)
      • mddionline.com (https://mddionline.com/manufacturing/medical-device-manufacturers-eye-costa-rica-as-tariff-uncertainty-shakes-up-production-strategies)
    7. Advanced Infrastructure for Clinical Trials
      • liveandinvestoverseas.com (https://liveandinvestoverseas.com/country-hub/costa-rica/health-care-in-costa-rica)
      • bestdentalhospitals.com (https://bestdentalhospitals.com/blog/best-hospitals-in-costa-rica-your-insiders-guide-to-finding-the-best-hospital-in-costa-rica)
      • data.who.int (https://data.who.int/countries/188)
      • oecd.org (https://oecd.org/en/publications/health-at-a-glance-2025_15a55280-en/costa-rica_3fb42541-en.html)
    8. Rapid Patient Recruitment Capabilities
    • Clinical Trials Patient Recruitment in Latin America | H Clinical (https://hclinical.com/patient-recruitment)
    • gitnux.org (https://gitnux.org/clinical-trial-recruitment-statistics)
    • Top 5 Clinical Trial Enrollment Metrics to Watch in 2026 (https://bekhealth.com/blog/clinical-trial-enrollment-metrics-2026)
    • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
    • healthcarecostarica.com (https://healthcarecostarica.com/biomedical-research)

  • Top 10 Considerations for Medtech Companies Entering Latin America

    Top 10 Considerations for Medtech Companies Entering Latin America

    Introduction

    Entering the Latin American market presents a unique set of opportunities and challenges, particularly in the medtech sector. With a diverse regulatory landscape and varying consumer preferences across countries, companies must adopt a strategic approach to ensure successful market penetration. Key factors such as:

    1. Regulatory compliance
    2. Thorough market research
    3. The establishment of strong distribution channels

    are essential for navigating this complex environment.

    Furthermore, understanding local cultural nuances and engaging in strategic partnerships can significantly enhance a company’s ability to connect with healthcare providers and consumers alike. As the region continues to evolve, a comprehensive understanding of these dynamics will be crucial for organizations aiming to thrive in the burgeoning Latin American medtech market.

    Key Factors for Successful Market Entry in Latin America

    Achieving successful entry in South America necessitates a strategic approach that encompasses several key factors:

    1. : Navigating the intricate landscape of regional regulations is essential. Each Latin American nation has unique regulations governing medical devices, and failure to comply can lead to significant obstacles, including delays or outright exclusion. To mitigate risks, include being proactive in understanding these regulations given the current environment. Notably, of the 43 companies that reached , the US government pursued at least 42 individuals related to the conduct of at least 10 companies, underscoring the .

    2. Industry Analysis: Comprehensive industry analysis is essential for understanding regional healthcare requirements, competitive dynamics, and suitable pricing strategies. A comprehensive understanding of these elements is among the , as it facilitates effective product positioning and enhances the likelihood of acceptance among consumers and healthcare providers.

      • Distribution Channels: Establishing the right is crucial for gaining access to healthcare providers and end-users. Effective distribution strategies are one of the , as they can significantly impact the reach and success of medical devices in the market. Developing a competitive pricing strategy that corresponds with regional economic conditions and consumer purchasing power is one of the . A well-considered approach to pricing can differentiate a product in a crowded marketplace.

    3. Regional Knowledge: Working with regional specialists and advisors can offer invaluable perspectives on industry dynamics and regulatory requirements. Their knowledge is one of the , as it can enhance a company’s strategy, leading to improved chances of success and smoother adherence to regional laws. In the context of recent trends, one of the is to prioritize strong anti-corruption policies, as highlighted by the ongoing challenges in the region. The Northern Triangle Enhanced Engagement Act underscores the necessity for , which has seen several former government officials face trials related to bribery and money laundering. As noted by Nicole M Argentieri, the Acting Assistant Attorney, ‘corporate criminal enforcement and individual accountability are two sides of the same coin,’ emphasizing the importance of self-disclosure and cooperation to build stronger compliance frameworks.

    Additionally, the comprehensive process for advancing in Colombia includes feasibility and selection of research sites, principal investigator (PI) selection, trial set-up, start-up, and approval through INVIMA approvals and ethics committee reviews, as well as study project management and monitoring. Companies such as Welwaze Medical Inc. and Hancock Jaffe Laboratories have effectively navigated this landscape, utilizing regional expertise through consulting firms like bioaccess™ to facilitate their . Bioaccess™ played a crucial role in guiding these companies through compliance and project management, ensuring a smoother entry into the Colombian market. These collaborations highlight the , showcasing Colombia’s competitive advantages such as cost efficiency, swift processes, high-quality healthcare, and incentives for research and development, making it an appealing location for first-in-human studies.

    BOOK A MEETING to discuss how we can assist you in advancing your medical device trials in South America.

    Navigating the compliance environment in South America requires a strategic approach that encompasses several critical factors:

    1. : Each country in Latin America has its own , such as ANVISA in Brazil and COFEPRIS in Mexico, alongside INVIMA in Colombia, which is recognized as a Level 4 health authority by PAHO/WHO. These agencies impose specific requirements for , and understanding these regulations is essential for compliance.
    2. Comprehensive : Conducting regional is often vital for demonstrating the safety and efficacy of . This process necessitates a thorough understanding of regional ethical standards and protocols, which can vary significantly from one country to another. As Katherine Ruiz, an expert in Regulatory Affairs for and In Vitro Diagnostics in Colombia, highlights, can greatly enhance compliance efforts and the overall success of clinical studies. Our service capabilities include feasibility studies and site selection to ensure optimal trial locations and principal investigator (PI) selection.
    3. : Familiarity with the is crucial. Companies must navigate the documentation requirements and timelines specific to each governing body to avoid costly delays in product launches. Notably, the transition to online submissions for medical device registrations is being implemented by several regulatory agencies, moving away from paper-based procedures. This shift is expected to enhance the efficiency of the registration process, although the pace of implementation varies by country. Our services also cover compliance reviews to ensure align with local requirements.
    4. : An in-depth understanding of the healthcare system’s structure—including both public and private sectors—within each country can inform effective market strategies and facilitate successful product placements. This knowledge is especially relevant as South America experiences a shift towards online submissions for medical device registrations.
    5. Effect on Nearby Economies: Participating in not only assists in compliance with regulations but also supports nearby economies through job creation and healthcare advancements. The , which has eliminated tariffs on about 90% of goods traded between member states, further facilitates trade and collaboration in the region. Furthermore, our project management services guarantee that studies are monitored efficiently, and reporting on study status, inventory, and adverse events is performed comprehensively.

    By taking these aspects into account and working with regional specialists, organizations can more effectively navigate the complex regulatory environment of Central and South America, which are among the top considerations for medtech companies entering Latin America, positioning themselves for successful entry and sustained growth in the medtech sector.

    The Role of Partnerships in Medtech Success

    One of the top considerations for medtech companies entering Latin America is the importance of for attaining success in the sector. Here are key avenues through which collaboration can yield significant benefits:

    1. : Partnering with established offers prompt access to a well-entrenched network and customer base, essential in a diverse environment characterized by varying regulations and consumer preferences.

      Their expertise can facilitate smoother market entry and reduce potential hurdles.

    2. : Partnerships with hospitals and clinics not only allow for product testing and validation but also foster trust with end-users. This collaboration is essential as can offer valuable insights into community needs and preferences, ultimately enhancing product acceptance.

    3. : Partnering with nearby is essential for maneuvering through the intricate compliance environment and performing required , such as those observed by Dushyanth Surakanti during the initial human trial of . These partnerships enhance the credibility of research efforts and ensure compliance with local standards, thereby facilitating smoother project execution.

    4. : Engaging with government bodies, including INVIMA, the Colombia National Food and Drug Surveillance Institute, is vital for understanding evolving policy landscapes and securing necessary approvals.

      This collaboration reduces risks related to compliance and assists in navigating potential challenges in the market.

    5. : Partnering with organizations that offer —including feasibility studies, site selection, compliance reviews, trial setup, import permits, project management, and reporting—can significantly enhance the efficiency and effectiveness of clinical research initiatives. These services ensure that all aspects of the trial are managed professionally, leading to better outcomes and adherence to regulatory standards.

    The trade balance of health equipment in the region of America and the Caribbean has reached an impressive 10 billion USD from 2018 to 2023, highlighting the immense potential for growth in this sector. This statistic underscores the top considerations for medtech companies entering Latin America, highlighting the importance of as companies look to capitalize on this growth. As Jennifer Mendoza, a research expert in health and medtech, emphasizes,

    Statista assumes no liability for the information given being complete or correct,

    which points to the necessity of thorough due diligence in partnerships.

    Furthermore, it is essential to recognize the , such as those faced during Avinger’s OCT-guided atherectomy research in Cali, Colombia. These challenges can significantly impact the success of medtech initiatives, emphasizing the need for ethical considerations and local engagement. Cultural exchange plays a fundamental role in enhancing mutual understanding among stakeholders, which can lead to innovative solutions and improved patient care.

    By fostering open dialogue and respect, stakeholders can build stronger connections that are essential for navigating the complexities of the American medtech landscape.

    Understanding Cultural Nuances and Consumer Preferences

    are among the top considerations for , particularly within the defined by authorities such as INVIMA, which oversees the safety and quality of medical devices. Understanding these elements is essential for companies, particularly in the context of the top considerations for , to thrive in the medtech sector.

    Language Considerations: Ensuring that marketing materials and product information are available in regional languages enhances both accessibility and comprehension.

    This is crucial, as studies indicate that significantly influences consumer trust and engagement in healthcare marketing. Moreover, addressing language barriers is one of the top considerations for , as they can hinder effective communication between US Medtech companies and regional stakeholders, complicating the execution of .

    Cultural Sensitivity: A deep understanding of and medical devices can shape effective marketing strategies and product designs.

    Understanding the top considerations for , including regional customs and values, is key to resonating with consumers in diverse markets.

    Consumer Behavior: —such as purchasing habits and preferences—provides insights for effective product positioning. A recent survey revealed that 73% of respondents had a positive outlook on , underscoring the trend toward digital channels in healthcare.

    Additionally, 37% of respondents expressed interest in a medication and lab test discount membership, which reflects some of the top considerations for to cater to these preferences.

    Regulatory Framework: is vital, as it ensures the compliance and safety of medical devices in the market. Establishing trust and credibility with consumers and healthcare providers alike is one of the top considerations for , making essential.

    Market Trends: The segment with the highest number of Healthtech startups in South America in 2023 is treatment, highlighting a growing area of opportunity for innovation and investment in the medtech sector.

    1. Resource Fragmentation: The fragmentation of resources and the absence of CRO corporate structures in South America pose significant challenges for US Medtech companies. These issues can lead to inefficient collaboration and hinder the successful implementation of clinical research.

    Feedback Mechanisms: Establishing robust channels for consumer feedback allows companies to adapt their offerings to better align with local needs. This responsiveness not only improves customer satisfaction but also cultivates long-term loyalty in a competitive environment.

    As the medtech sector continues to progress in South America, the Top Considerations for will include addressing cultural nuances and consumer preferences, along with a strong understanding of compliance dynamics and existing challenges, which will be crucial for success.

    Identifying and Mitigating Market Entry Risks

    Reducing market entry risks in South America requires a multifaceted strategy, and one of the top considerations for medtech companies entering Latin America is grasping the . For instance, INVIMA (Colombia National Food and Drug Surveillance Institute) plays a pivotal role in overseeing the marketing and manufacturing of health products. Established in 1992, INVIMA is responsible for ensuring compliance with health standards and implementing of medical devices.

    Its classification as a Level 4 health authority by PAHO/WHO underscores its competence in guaranteeing the safety, efficacy, and quality of health products.

    Here are essential strategies:

    1. Economic Volatility: Understanding the is critical, especially as inflation persists in various Latin American countries, raising concerns about price stability. The projected increase of the population aged 65 and older to 20.6% by 2053 underscores the urgency for stable healthcare solutions.

      Companies must analyze these economic conditions and potential fluctuations to better prepare for financial uncertainties.

    2. : The medtech sector must stay alert concerning compliance updates. Recent reforms, such as those championed by President Lacalle Pou in Uruguay, which raised the retirement age to 65 and allowed retirees to continue working, illustrate the shifting regulatory environment aimed at modernizing systems.

      Staying informed about these changes can prevent compliance issues and operational disruptions, ensuring smoother entry into the industry.

    3. Compliance Best Practices: Engaging with INVIMA requires adherence to specific best practices, such as thorough documentation of product specifications and , timely submission of applications, and proactive communication with INVIMA officials.

      Companies should also familiarize themselves with and participate in training sessions or workshops to enhance compliance understanding.

    4. Competitive Analysis: A thorough competitive analysis is essential to identify key industry players and potential challenges. Companies can utilize insights from case studies, particularly on wealth taxes as tools for economic reform, to understand the competitive landscape and anticipate shifts in industry dynamics.

      These wealth taxes have gained prominence as a means to reduce inequality and generate resources for combating global warming, which can significantly influence company strategies.

    5. Political Stability: Assessing the is essential for understanding governance and policy risks. With borrowing costs for issuers in South America and the Caribbean widening significantly—evidenced by LAC bond spreads reaching 471 basis points compared to the overall EMBIG at 305 basis points—companies must analyze political stability to navigate effectively.

      These statistics provide a concrete example of the and its implications for market entry, emphasizing the top considerations for medtech companies entering Latin America.

    By integrating these strategies, firms can better position themselves to enter the Latin American market with a nuanced understanding of the associated risks and opportunities, particularly considering in medtech regulation and its impact on local economies through job creation and healthcare improvement.

    Additionally, understanding the specific functions of the Directorate for Medical Devices and other Technologies within INVIMA can further enhance compliance and operational strategies.

    Conclusion

    Entering the Latin American medtech market requires a well-rounded strategy that addresses key factors such as regulatory compliance, thorough market research, and the establishment of strong distribution channels. Companies must prioritize understanding the diverse regulatory landscapes across different countries, as compliance is not merely a formality but a critical component that can determine market success or failure.

    Moreover, engaging in comprehensive market research is essential for identifying local healthcare needs and consumer preferences. This knowledge is pivotal for crafting effective pricing strategies and positioning products in a manner that resonates with both healthcare providers and consumers. Establishing robust distribution partnerships further enhances market access and facilitates smoother entry into the dynamic Latin American landscape.

    Cultural nuances and local consumer behaviors play significant roles in shaping successful marketing strategies. Companies that prioritize language accessibility, cultural sensitivity, and feedback mechanisms are more likely to build trust and foster long-term relationships with their target audiences. Additionally, forming strategic partnerships with local distributors, healthcare providers, and research institutions can provide invaluable insights and facilitate compliance with local regulations.

    As the medtech sector in Latin America continues to grow, organizations must remain vigilant in identifying and mitigating market entry risks. By understanding economic volatility, regulatory changes, and the competitive landscape, firms can navigate potential challenges and seize opportunities in this burgeoning market. Ultimately, a holistic approach that combines compliance, market understanding, and strategic collaboration is essential for achieving sustainable success in the Latin American medtech industry.

    Frequently Asked Questions

    What are the key factors for successful entry into the South American market for medtech companies?

    Successful entry necessitates a strategic approach focusing on regulatory compliance, comprehensive industry analysis, and regional knowledge.

    Why is regulatory compliance important for medtech companies in South America?

    Navigating regional regulations is crucial as each Latin American nation has unique requirements for medical devices. Non-compliance can lead to significant obstacles, including delays or exclusion from the market.

    What should medtech companies consider regarding industry analysis?

    Companies should conduct a comprehensive analysis to understand healthcare requirements, competitive dynamics, and pricing strategies, which facilitate effective product positioning and acceptance among consumers and healthcare providers.

    How do distribution channels impact market entry?

    Establishing the right distribution partnerships is vital for accessing healthcare providers and end-users, significantly influencing the reach and success of medical devices in the market.

    What is the role of regional knowledge in entering the South American market?

    Working with regional specialists and advisors provides invaluable insights into industry dynamics and regulatory requirements, enhancing a company’s strategy and compliance efforts.

    What are the implications of anti-corruption policies for medtech companies?

    Prioritizing strong anti-corruption policies is essential due to ongoing challenges in the region, with recent legislation emphasizing the necessity for robust compliance measures.

    What is involved in the process of advancing medical device trials in Colombia?

    The process includes feasibility studies, site selection, principal investigator selection, trial setup, and obtaining approvals from INVIMA and ethics committees, as well as project management and monitoring.

    How can companies ensure compliance during clinical trials in South America?

    Companies should conduct regional clinical trials with a thorough understanding of local ethical standards and protocols, and utilize services that cover compliance reviews and documentation alignment.

    What changes are being made to the approval processes for medical devices?

    Regulatory agencies are transitioning to online submissions for medical device registrations, enhancing the efficiency of the registration process, though the pace varies by country.

    How does participation in clinical trials affect local economies?

    Conducting clinical trials supports local economies by creating jobs and advancing healthcare, while agreements like MERCOSUR facilitate trade and collaboration in the region.

    List of Sources

    1. Key Factors for Successful Market Entry in Latin America
      • latinlawyer.com (https://latinlawyer.com/guide/the-guide-corporate-compliance/fifth-edition/article/analysis-of-latin-americas-compliance-climate-indicates-anti-corruption-efforts-the-rise)
    2. Navigating Regulatory Landscapes and Healthcare Systems
      • blog.bioaccessla.com (https://blog.bioaccessla.com/how-to-navigate-regulatory-requirements-for-medical-devices-in-latin-america-a-step-by-step-guide)
      • mddionline.com (https://mddionline.com/regulatory-quality/latin-american-medical-device-regulations)
      • insights.omnia-health.com (https://insights.omnia-health.com/management/insights-regional-medical-devices-regulatory-affairs-reach-latam)
    3. The Role of Partnerships in Medtech Success
      • statista.com (https://statista.com/topics/6562/medical-technology-in-latin-america)
      • blog.bioaccessla.com (https://blog.bioaccessla.com/understanding-us-latin-american-collaboration-in-med-tech-an-in-depth-tutorial)
      • blog.bioaccessla.com (https://blog.bioaccessla.com/why-exploring-med-tech-collaboration-between-the-us-and-latin-america-is-essential-for-innovation)
    4. Understanding Cultural Nuances and Consumer Preferences
      • statista.com (https://statista.com/outlook/hmo/medical-technology/medical-devices/latam)
      • mckinsey.com (https://mckinsey.com/industries/healthcare/our-insights/healthcare-in-latin-america-what-are-consumers-looking-for)
      • globalhealthintelligence.com (https://globalhealthintelligence.com/ghi-analysis/latams-best-selling-medical-equipment)
      • statista.com (https://statista.com/topics/6562/medical-technology-in-latin-america)
    5. Identifying and Mitigating Market Entry Risks
      • www2.deloitte.com (https://www2.deloitte.com/us/en/insights/economy/americas/latin-america-economic-outlook.html)
      • worldbank.org (https://worldbank.org/en/region/lac/publication/perspectivas-economicas-america-latina-caribe)
      • cepal.org (https://cepal.org/en/notes/capital-flows-latin-america-and-caribbean-five-charts-first-ten-months-2024)

  • 5 Questions Every MedTech Team Asks Before Running Their First-in-Human Trial in Latin America

    On May 8, 2026, 98 MedTech professionals from 17 countries joined our Friday In Focus webinar on running first-in-human (FIH) clinical trials in Latin America. 59% stayed past 46 minutes in a 62-minute session — and they didn’t ask curiosity questions. They asked execution questions: country selection, ethics, FDA acceptability, statistical power, step-by-step playbooks for medical device sponsors who are actively planning their first FIH outside the United States.

    If you’re evaluating whether to run your next first-in-human study in Latin America, here are the five questions your peers pushed hardest on — and how to think about each one before you commit to a country, an ethics committee, or an FDA submission strategy.

    1. Which country in Latin America is the easiest?

    This was the first question out of the gate, asked by Rocío Paublete (Sweden, PMCF & Clinical Investigation Project Manager) and echoed throughout the chat. The honest answer is: it depends on what you’re optimizing for.

    “Easy” decomposes into three orthogonal dimensions:

    • Patient recruitment speed — how quickly you can enroll the first 5–30 patients for an FIH or early feasibility study. Colombia, Mexico, and Brazil typically lead here because of dense urban hospital networks and high physician engagement with research.
    • Ethics committee turnaround — how long the IRB/CEI review cycle takes from submission to approval. Chile and Costa Rica run faster review cycles than Brazil, where amendments through CONEP can stretch.
    • Regulatory authority predictability — INVIMA (Colombia), ANVISA (Brazil), COFEPRIS (Mexico), ANMAT (Argentina), DIGEMID (Peru), and ISP (Chile) all have different timelines, fee structures, and documentation expectations.

    For most US-headquartered MedTech sponsors running an FIH, the practical sweet spot is Colombia or Costa Rica for first-patient-in speed, with Brazil considered when the indication requires larger patient diversity or when the eventual commercial path runs through Latin America’s largest market.

    2. Are those countries easier because of recruitment, or because of ethics committees?

    Rocío came back with this follow-up — and it’s the right one to ask. The two drivers behave differently:

    • Recruitment speed is largely a function of investigator network density, hospital infrastructure, and patient population. It’s a relatively stable property of the country and the indication.
    • Ethics committee speed varies by which committee, not just which country. A Bogotá-based academic medical center’s CEI may turn around in 4–6 weeks; a regional committee might take 12. The same country can deliver dramatically different timelines depending on site selection.

    The implication for sponsors: pick countries where both the recruitment and the committee math work, then pick sites where you’ve already mapped CEI cycle times empirically. Don’t optimize one without the other.

    3. Will the FDA accept clinical data generated in Latin America?

    This question, from Bhavik Gondaliya (Germany, RA), is the one that gates every conversation about whether LatAm FIH data will actually contribute to a US regulatory submission. The short answer: yes, with conditions.

    The FDA’s longstanding position on foreign clinical data is codified in 21 CFR 814.15 for PMA submissions and reflected in their 2018 guidance “Acceptance of Clinical Data to Support Medical Device Applications and Submissions.” LatAm data is acceptable if:

    • The study was conducted in accordance with Good Clinical Practice (GCP), including independent ethics review and informed consent
    • The data are applicable to the US patient population (the FDA looks for population overlap on the relevant clinical and demographic axes)
    • The site investigators were qualified, the protocol was scientifically sound, and the data are auditable by FDA inspectors

    For most early-stage MedTech sponsors, the practical playbook is to design the LatAm FIH so that its protocol, endpoints, and case report forms look like what an FDA reviewer would expect to see in a US pivotal study. Doing this work upfront makes the eventual bridging to a US IDE or 510(k)/De Novo dramatically smoother.

    4. How do you handle the ethics of providing investigational therapy “for free” in lower-resource settings?

    Nyerngoor Korda Hewitt (UK, Director of Regulatory Affairs and Quality) raised this — and it’s a question every sponsor should be ready for. The concern is real: when an FIH protocol provides expensive investigational therapy at no cost in a country where standard care is often unaffordable, you can create undue inducement.

    The frameworks that govern this are well-established — the Declaration of Helsinki (especially Articles 19–20 on vulnerable populations), the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, and country-specific implementations. Operationally, robust sponsors design their LatAm FIH protocols to address inducement directly:

    • Post-trial access — explicit commitments about whether participants will continue to receive the therapy after the trial ends, and under what conditions
    • Standard-of-care arms — when ethically and statistically appropriate, designing comparator arms so participants aren’t forced to choose between trial enrollment and accessible care
    • Independent ethics review in the host country, with documented review of the inducement question by the local CEI
    • Community engagement — particularly for indications where the trial may shape future access in the country

    The audience response on this question made clear: it’s a topic experienced sponsors and their RA teams take seriously, and one ethics committees in Colombia, Mexico, Chile, and elsewhere actively probe.

    5. Step-by-step: I have a de novo medical device and I want to do FIH in Panama or Bolivia. What does it actually look like?

    This question, from Joseph Skraba (University of Texas at Austin, Manager of Medical Device Commercialization), was the most operational of the session. Here’s the compressed playbook for a de novo Class II/III medical device sponsor:

    1. Pre-clinical foundation — bench testing, biocompatibility (ISO 10993), sterilization validation, and animal study data sufficient to support first human exposure. This is non-negotiable.
    2. FDA pre-submission (Q-Sub) is optional but strongly recommended — even for studies conducted entirely outside the US, a Q-Sub conversation aligns the FDA’s expectations for how the foreign data will support a future US submission. This is “free insurance” for your eventual regulatory path.
    3. Export approval — for a non-US-cleared device, you’ll need an FDA Export Certificate (typically a Certificate to Foreign Government, CFG) under Section 801(e) of the FD&C Act. Lead time is usually 4–6 weeks.
    4. In-country regulatory approval — country-specific medical device authorization. INVIMA (Colombia) and ANMAT (Argentina) have streamlined pathways for clinical investigation devices; smaller markets like Panama and Bolivia rely on Ministry of Health approvals that vary in predictability. Plan 8–16 weeks.
    5. Ethics committee review — single-site or multi-site CEI approval. Allow 4–12 weeks depending on country and committee. Many sponsors run this in parallel with regulatory.
    6. Site activation — investigator agreements, indemnification (and clinical trial insurance — required in most LatAm countries), training on the IFU and protocol, IRT/EDC system rollout.
    7. First-patient-in — typically 6–9 months from kickoff for a well-prepared sponsor, faster with an experienced in-country CRO.

    The realistic end-to-end timeline from contracting to first-patient-in is 6–9 months for sponsors who arrive prepared, longer for sponsors who try to compress pre-clinical or skip the FDA Q-Sub.

    Bonus: “Statistical power with 5 patients?”

    Stephanie Grassmann (Switzerland, MedTechXperts LLC) lobbed this one in — and the answer is: FIH studies aren’t powered for inferential statistics, and that’s by design.

    An FIH/early-feasibility study (typically 5–30 patients) is designed to evaluate safety, device handling, procedural success, and preliminary signals of efficacy. The endpoints are descriptive: rates, intervals, mean changes from baseline. The next study (pilot or pivotal, often 50–300+ patients) is where powered hypothesis testing begins. The two studies serve different scientific purposes and are evaluated by the FDA on different criteria.

    For sponsors evaluating whether their LatAm FIH will “count” toward their eventual US submission: it counts if it answers the questions a 5–30 patient study is designed to answer. Don’t try to make it carry weight it wasn’t designed to bear.

    Who was in the room

    The 98 attendees came from 17 countries across North America, Europe, Latin America, and Asia, with roles ranging from Regulatory Affairs leaders and Quality directors to MedTech founders and CEOs. The session ran from 11:00 AM to 12:02 PM ET on Friday, May 8, 2026, and 20% of listeners stayed for the final two minutes — an engagement signal that tracks with the seriousness of the questions asked.

    Next steps for your team

    If your team is actively planning a first-in-human study and wrestling with any of the questions above, here’s how to move forward:

    • Free 30-minute feasibility screen — share your indication, target patient count, and target FPI date, and we’ll tell you which 2–3 LatAm countries are realistic for your specific case. Book a call →
    • Read the case studies — bioaccess® has supported FIH and early-feasibility studies for cardiology, neurology, ophthalmology, and orthopedic device sponsors across Colombia, Mexico, Chile, Costa Rica, and Brazil. See recent case studies →
    • Stay current — we publish new analyses of LatAm regulatory shifts (ANVISA’s 2026–2027 international convergence agenda, FDA’s December 2025 RWE guidance and what it means for LatAm data, ophthalmic FIH dynamics in smaller markets) every week. Subscribe via the form below.

    Thanks to the 98 MedTech professionals who joined the session, and to the panelists and moderators who made the depth of the discussion possible. The next Friday In Focus session will be announced shortly.

  • 7 Ways cfg Enhances Clinical Research Agility for MedTech

    7 Ways cfg Enhances Clinical Research Agility for MedTech

    Introduction

    In the rapidly evolving landscape of clinical research, navigating complex regulatory frameworks and expediting trial processes is paramount for MedTech and Biopharma companies. bioaccess® emerges as a frontrunner, offering unparalleled agility that not only accelerates clinical trials but also enhances patient access to innovative medical solutions.

    With a proven track record of achieving ethical approvals in a mere 4-6 weeks and facilitating patient enrollment at twice the speed of traditional markets, bioaccess® is redefining the standards of efficiency in clinical research.

    As the demand for rapid market entry intensifies, understanding how bioaccess® leverages diverse patient populations and regional regulatory advantages becomes essential for any organization aiming to thrive in this competitive sector.

    bioaccess®: Accelerate Clinical Research with Global-First Agility

    The company distinguishes itself in the medical research field by providing remarkable agility through a strategic combination of regulatory speed, varied patient demographics, and efficient processes. This distinctive method enables MedTech and Biopharma firms to , significantly shortening time-to-market for . With over 20 years of industry experience, the company effectively , achieving and facilitating patient enrollment that is 50% faster than traditional markets.

    The segment is anticipated to expand at an impressive CAGR of 16.4%, highlighting the rising need for effective research procedures. This growth presents an opportunity for bioaccess® to enhance its service offerings, including:

    1. Site selection
    2. Testing setup
    3. Import permits
    4. Reporting

    This strategically positions itself as a leader in facilitating rapid research assessments. Recent advancements, such as the incorporation of wearable devices in phase I studies, enhance patient monitoring and study efficiency, further accelerating drug development.

    In Europe, the research technology environment is experiencing considerable advancement, propelled by regulatory factors from the European Medicines Agency and GDPR. The UK’s National Health Service is adopting digital tools to simplify participation in studies, emphasizing a shift towards , supported by government investments in healthcare IT infrastructure.

    The dedication to research flexibility establishes bioaccess® as an essential ally for MedTech innovators, guaranteeing that they can navigate the intricacies of trials with swiftness and accuracy. This agility not only enhances the likelihood of successful outcomes but also fosters successful partnerships within the MedTech sector, ultimately advancing the development of life-changing medical technologies. As Brian Moore, VP of NICCA USA, Inc., stated, ‘The quality of research they have conducted for us has been outstanding,’ underscoring the trust and dependability that the brand brings to its partnerships. Moreover, a strategic approach to is vital for optimizing enrollment efficiency, a primary focus area for bioaccess® as it continues to assist its clients in achieving their research objectives.

    Early-Phase Studies: Essential for Rapid Market Entry

    , particularly and , play a critical role in the . These investigations yield essential insights regarding safety, dosage, and efficacy, which are vital for regulatory submissions. By optimizing these processes, this solution empowers MedTech companies to swiftly validate their innovations, facilitating a quicker transition to market entry. This is not just beneficial; it is crucial for sustaining a competitive edge in the rapidly evolving MedTech industry.

    Statistics reveal that 92.3% of experiments utilizing biomarkers have commenced since January 1, 2005, underscoring the growing reliance on early-phase evaluations to inform research design and execution. Furthermore, the challenges associated with accentuate the necessity for and analysis, a need that this solution effectively addresses through robust methodologies. As the continues to transform, the significance of in streamlining market entry and bolstering clinical development remains paramount.

    Leverage Latin America’s Regulatory Speed for Faster Approvals

    Latin America presents a distinctive regulatory environment that significantly accelerates , often completing processes within just 4-6 weeks. This rapid pace serves as a cornerstone of the strategy, enabling MedTech companies to initiate studies more swiftly. By skillfully navigating the , this platform empowers innovators to bring their products to market faster, ultimately enhancing patient access to groundbreaking . The benefits of this regulatory pace are underscored by the region’s , even though the International Council for Harmonisation (ICH) guidelines have not been officially embraced in numerous LATAM nations. This gap presents an opportunity for organizations like bioaccess® to implement efficient processes that align with global standards, thereby improving drug approval timelines.

    As we look to 2025, the focus on continues to expand, with trials benefiting from . For instance, the average time for in the region remains significantly shorter than in traditional markets, which can take several months to years. This efficiency not only accelerates the creation of groundbreaking medical devices but also positions Latin America as a strategic center for medical research.

    To achieve , MedTech companies can leverage local expertise and regulatory knowledge, ensuring compliance while expediting their pathways to market. By embracing the unique advantages of Latin America’s regulatory framework, companies can and ultimately improve patient outcomes.

    This flowchart shows how MedTech companies can move from leveraging local knowledge to achieving faster ethical approvals. Follow the arrows to see each step in the process and how they connect.

    Utilize Diverse Patient Pools in the Balkans for Enhanced Research Outcomes

    The Balkans represent a rich and varied demographic environment, which is essential for medical research. By leveraging this diversity, bioaccess™ significantly enhances the quality and relevance of research outcomes. facilitate , ensuring that findings accurately reflect a wide range of populations. This diversity is particularly vital for , as it provides .

    Research has consistently demonstrated that yields more robust and relevant outcomes, with . Moreover, has been shown to enhance patient comfort and willingness to participate, thereby .

    As the landscape of medical research evolves, the importance of cannot be overstated, particularly in the Balkans, where and the overall effectiveness of medical innovations.

    At the center is the main idea, and the branches show key benefits and related concepts, illustrating how diversity enhances research quality and participant engagement.

    Ensure Ethical Approvals in 4-6 Weeks with bioaccess®

    bioaccess® guarantees ethical approvals within an impressive timeframe of 4-6 weeks, establishing itself as a leader in the arena. This rapid turnaround is made possible by a profound and proactive collaboration with ethics committees. Notably, protocols overseen by local researchers have demonstrated of only 47.08 days, with Phase 2 trials averaging just 25.54 days. Such efficiency not only mitigates delays in initiating proceedings but also empowers MedTech firms to sustain momentum in their product development schedules.

    In a landscape where the for reviewers lacking matching expertise, the streamlined process—which encompasses:

    • study setup
    • study document review
    • comprehensive

    offers a . This ensures that innovations reach the market faster and more effectively.

    Achieve Cost-Effective Clinical Research Solutions with bioaccess®

    This company offers tailored research solutions that seamlessly integrate high quality with cost-effectiveness. With over 20 years of expertise in Medtech, the organization optimizes operational procedures and utilizes local resources, significantly reducing overall project expenses for MedTech firms. This financial efficiency is particularly advantageous for startups and smaller companies, enabling them to maximize their investments while adhering to .

    , with the . By focusing on budget-friendly strategies, the organization enhances the economic viability of medical trials and accelerates the advancement of and , ultimately benefiting both patients and healthcare systems.

    As Patricio Ledesma, Head of Clinical Operations and Founder, articulates, “Offering is vital for biotechnology and pharmaceutical companies navigating trials and drug development.”

    Furthermore, this organization emphasizes a , including:

    These studies are essential for the successful progression of . The case study titled ‘Funding and Support for the Study’ exemplifies how , ensuring that funding sources do not sway study design or reporting.

    Additionally, the partnership with Flow-FX for its inaugural human trial of the Flow-Screw device in Colombia showcases the organization’s commitment to and supporting local economic development.

    The central node outlines the main focus on cost-effective solutions, while the branches represent important aspects like study types and expert advice. Follow the branches to explore each area further.

    Customize Your Clinical Research Strategy with bioaccess®

    The organization recognizes that each MedTech innovation presents unique challenges, necessitating a . By fostering close collaboration with clients, bioaccess® develops tailored plans that align with specific project objectives and regulatory frameworks. This personalized methodology enhances every facet of the research process, from to , thereby ensuring a greater likelihood of success.

    In 2025, the significance of customized studies is underscored by data indicating that tailored approaches can yield improved success rates in medical research. Research shows that generate valid and generalizable outcomes, highlighting the critical nature of . Furthermore, can uncover patterns and inspire new research inquiries, thus advancing medical understanding and innovation in the field.

    With over 20 years of experience, the organization excels in that not only meet but also enhance the overall effectiveness of studies. This commitment to tailored solutions positions the company as a leader in facilitating the rapid advancement of .

    The center represents the overall strategy, with branches showing essential components and their connections, illustrating how each part contributes to successful medical research.

    Overcome Recruitment Challenges with bioaccess® Support

    Recruitment remains one of the most formidable challenges in . This program addresses these hurdles through a suite of innovative strategies, including and . By gaining a deep understanding of and fostering strong relationships with healthcare providers, bioaccess® significantly enhances recruitment efforts. This method not only guarantees that experiments are adequately powered but also promotes .

    For instance, a recent case analysis highlighted the complexities of recruiting for , where the need for homogeneous patient groups complicates the process. It underscored the importance of deploying innovative to effectively identify individuals with specific biological markers. Furthermore, statistics indicate that research financed by government bodies frequently undergoes a greater rate of changes, highlighting the necessity for flexible .

    By utilizing social media to link patients and exchange experiences, the organization fosters a supportive atmosphere that promotes involvement, ultimately resulting in enhanced success rates in .

    Follow the arrows to see how each strategy helps tackle recruitment challenges. Each strategy is a step towards creating a more inclusive and effective recruitment process.

    Maintain Compliance with Regulations and Protocols in Clinical Trials

    This organization emphasizes the necessity of adhering to all relevant regulations and protocols during the research process. By continuously monitoring the latest guidelines and best practices, bioaccess® guarantees that research is conducted ethically and responsibly. This unwavering not only safeguards patient safety but also bolsters the trustworthiness of research outcomes.

    The significance of in cannot be overstated. A recent evaluation revealed that , highlighting the urgent need for a more robust focus on this aspect. Research indicates that typically demonstrate improved reporting and , which are essential for precise evaluations of safety and efficacy.

    Expert insights emphasize that substantial statistical analyses should incorporate medication adherence, as noted by . He asserts that compliance should be accounted for at least during ‘post-adjustment’ procedures to enhance the evaluation of experimental drugs. Katherine Ruiz, an expert in regulatory affairs for medical devices and in vitro diagnostics in Colombia, reinforces this perspective by advocating for the integration of compliance metrics into analytical processes, ensuring that assessments are comprehensive and reflective of actual conditions.

    Moreover, case examples reveal the real-world impacts of medication noncompliance, uncovering significant . These findings advocate for healthcare reforms aimed at enhancing adherence, which is crucial for mitigating adverse effects on public health and curtailing healthcare costs. At our organization, we address these implications by designing our research to promote adherence and closely monitor compliance, thereby improving .

    As we approach 2025, the dialogue surrounding adherence in research trials continues to evolve, with increasing recognition of its influence on trial results. At bioaccess®, our commitment to , including cfg , is not merely a requirement; it is a fundamental aspect of ensuring the success and integrity of research in the MedTech sector.

    Start at the center with the main theme of compliance. As you follow the branches, you'll discover various related topics and insights. Each color-coded branch represents a different aspect of compliance, helping you see how they all connect to the central idea.

    Transition from First-in-Human Studies to Commercialization with bioaccess®

    Transitioning from to commercialization is a multifaceted journey that demands meticulous planning and execution. With approximately , leading to significant financial setbacks, the importance of cannot be overstated. The company provides essential support throughout this critical process, offering that include:

    • Feasibility assessments
    • Site selection
    • Compliance reviews
    • Setup
    • Import permits
    • Project management
    • Progress reporting
    • Document feedback

    This enables MedTech companies to effectively navigate the intricate regulatory landscape, develop robust , and implement effective .

    The organization’s expertise is particularly valuable in identifying , as research indicates that , correlate with higher success rates in clinical trials. By utilizing these insights, this platform assists innovators in improving their chances of successful transitions from FIH studies to market launch.

    In 2025, tailored to specific market requirements. This brand stands at the forefront of this evolution, ensuring that innovations not only reach the market efficiently but also deliver tangible benefits to patients and healthcare providers alike. Through comprehensive support at every stage, including collaboration with partners like Welwaze Medical Inc. for the Celbrea® launch in Colombia, bioaccess® is committed to advancing MedTech innovations and facilitating their journey to commercialization.

    Conclusion

    The landscape of clinical research is undergoing rapid transformation, with bioaccess® at the forefront, pioneering innovative strategies that expedite trial processes and regulatory approvals. By securing ethical approvals in a mere 4-6 weeks and significantly enhancing patient recruitment efficiency, bioaccess® empowers MedTech and Biopharma companies to accelerate the market entry of their groundbreaking medical solutions. This agility is not only vital for sustaining a competitive edge but also for enhancing patient access to essential healthcare advancements.

    The strategic engagement of diverse patient populations, particularly in regions such as Latin America and the Balkans, further elevates the quality of research outcomes. By leveraging local expertise and adeptly navigating regulatory frameworks, bioaccess® guarantees that clinical trials are both compliant and representative of a broad spectrum of demographics. This diversity is crucial for the development of medical innovations that are relevant across various populations, ultimately fostering improved health outcomes.

    In a high-stakes sector with tight timelines, bioaccess® distinguishes itself as a trusted ally for organizations striving for success in clinical research. Its dedication to tailored solutions and robust methodologies positions it as a leader in the field, facilitating the transition from initial studies to commercialization. As the demand for swift market entry continues to escalate, bioaccess® is uniquely poised to tackle these challenges, ensuring that the future of medical technology remains promising and accessible for all.

    Frequently Asked Questions

    What distinguishes bioaccess® in the medical research field?

    bioaccess® distinguishes itself by providing remarkable agility through a strategic combination of regulatory speed, varied patient demographics, and efficient processes, enabling MedTech and Biopharma firms to accelerate their studies and shorten time-to-market for innovative medical solutions.

    How quickly can bioaccess® achieve ethical approvals?

    bioaccess® can achieve ethical approvals in just 4–6 weeks.

    What is the expected growth rate for the phase I research segment?

    The phase I research segment is anticipated to expand at a CAGR of 16.4%.

    What services does bioaccess® offer to enhance research procedures?

    bioaccess® offers feasibility studies, site selection, compliance reviews, testing setup, import permits, project management, and reporting.

    How does the incorporation of wearable devices impact phase I studies?

    The incorporation of wearable devices enhances patient monitoring and study efficiency, further accelerating drug development.

    What advancements are occurring in the European research technology environment?

    The European research technology environment is advancing due to regulatory factors from the European Medicines Agency and GDPR, with the UK’s National Health Service adopting digital tools to simplify participation in studies.

    Why are early-phase studies important in clinical development?

    Early-phase studies, particularly First-in-Human (FIH) and Early-Feasibility Evaluations (EFS), are critical for yielding insights regarding safety, dosage, and efficacy, which are essential for regulatory submissions and quicker market entry.

    What percentage of experiments utilizing biomarkers have started since January 2005?

    Statistics reveal that 92.3% of experiments utilizing biomarkers have commenced since January 1, 2005.

    How does Latin America’s regulatory environment benefit MedTech companies?

    Latin America’s regulatory environment significantly accelerates ethical approvals, often completing processes within 4-6 weeks, enabling MedTech companies to initiate studies more swiftly and enhance patient access to medical solutions.

    What strategies can MedTech companies use to achieve faster ethical approvals in Latin America?

    MedTech companies can leverage local expertise and regulatory knowledge to ensure compliance while expediting their pathways to market, enhancing research agility and improving patient outcomes.

    List of Sources

    1. bioaccess®: Accelerate Clinical Research with Global-First Agility
      • Clinical Trial Technology And Services Market Size Report, 2025-2030 (https://grandviewresearch.com/industry-analysis/clinical-trial-technology-services-market-report)
      • What clinical trial statistics tell us about the state of research today (https://antidote.me/blog/what-clinical-trial-statistics-tell-us-about-the-state-of-research-today)
    2. Early-Phase Studies: Essential for Rapid Market Entry
      • Checking your browser – reCAPTCHA (https://pmc.ncbi.nlm.nih.gov/articles/PMC6409418)
    3. Leverage Latin America’s Regulatory Speed for Faster Approvals
      • us.anteagroup.com (https://us.anteagroup.com/news-events/blog/6-quotes-tech-leaders-can-inspire-your-ehs-initiatives)
      • wilsoncenter.org (https://wilsoncenter.org/event/environmental-leadership-latin-american-perspectives-climate-crisis)
      • Clinical Trials in Latin America (https://languageconnections.com/clinical-trials-in-latin-america)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10579156)
      • pharmoutsourcing.com (https://pharmoutsourcing.com/Featured-Articles/37848-Latin-America-vs-Other-Emerging-and-Non-Emerging-Markets-in-Clinical-Research-Regulations-Investigators-and-Ethics-Committees)
    4. Utilize Diverse Patient Pools in the Balkans for Enhanced Research Outcomes
      • Key Trends in Demographic Diversity in Clinical Trials – Improving Representation in Clinical Trials and Research – NCBI Bookshelf (https://ncbi.nlm.nih.gov/books/NBK584392)
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • SCIRP Open Access (https://scirp.org/journal/paperinformation?paperid=128354)
      • Enrollment in Clinical Trials: Statistics and Patient Recruitment Strategies | Power (https://withpower.com/guides/enrollment-in-clinical-trials-statistics-and-patient-recruitment-strategies)
    5. Ensure Ethical Approvals in 4-6 Weeks with bioaccess®
      • tghncollections.pubpub.org (https://tghncollections.pubpub.org/pub/7qecajvo)
      • latam-podcast.buzzsprout.com (https://latam-podcast.buzzsprout.com/270132/episodes/12320840-ernesto-m-nogueira-ceo-at-valueconnected)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10693024)
    6. Achieve Cost-Effective Clinical Research Solutions with bioaccess®
      • The Ultimate Guide to Clinical Trial Costs in 2025 (https://sofpromed.com/ultimate-guide-clinical-trial-costs)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC7295430)
      • sofpromed.com (https://sofpromed.com/how-much-does-a-clinical-trial-cost)
      • statnews.com (https://statnews.com/pharmalot/2020/06/18/clinical-trials-drug-development-prices)
    7. Customize Your Clinical Research Strategy with bioaccess®
      • americanpharmaceuticalreview.com (https://americanpharmaceuticalreview.com/Featured-Articles/611945-Precision-Medicine-in-Clinical-Trials-A-Statistical-Perspective)
      • aomics.com (https://aomics.com/role-of-statistical-analysis-in-clinical-research)
      • lindushealth.com (https://lindushealth.com/blog/understanding-clinical-trial-statistics-a-comprehensive-guide)
    8. Overcome Recruitment Challenges with bioaccess® Support
      • Why participant recruitment remains the biggest challenge in clinical trials (https://linkedin.com/pulse/why-participant-recruitment-remains-biggest-challenge-arb0e)
      • Clinical studies: the challenge of patient recruitment (https://servier.com/en/newsroom/clinical-studies-patient-recruitment)
      • labiotech.eu (https://labiotech.eu/expert-advice/clinical-trial-recruitment)
      • Uncovering key clinical trial features influencing recruitment – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC10565197)
    9. Maintain Compliance with Regulations and Protocols in Clinical Trials
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC5934909)
      • sciencedirect.com (https://sciencedirect.com/science/article/pii/S0895435622002360)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC3109858)
    10. Transition from First-in-Human Studies to Commercialization with bioaccess®
    • Estimation of clinical trial success rates and related parameters (https://academic.oup.com/biostatistics/article/20/2/273/4817524)
    • knowledgeportalia.org (https://knowledgeportalia.org/r-d-time-and-success-rate)
    • statista.com (https://statista.com/topics/6756/clinical-trials)
    • Factors Affecting Success of New Drug Clinical Trials – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC10173933)